


APRIL 26-29, 2017  
SAN FRANCISCO, CALIFORNIA

**SWOG**  Leading cancer research. Together.

# San Francisco





# Celebrating Innovation in San Francisco

*Our work is not a static process. Every day, we try to identify better treatments, or screening methods, or ways to relieve pain, or even how to identify new drug targets. Our tools are also ever-changing: new assays, new trial designs, new ways to collect and crunch data.*

SWOG members are seekers of relentless improvement. Innovation is required to conduct cancer clinical trials, and this spirit of innovation is the theme for our 2017 group meetings. Here in San Francisco, we'll hear plenary presentations from SWOG executive officers on our most cutting-edge treatment trials operating today. We'll get the latest on improvements to ClinicalTrials.gov – the world's biggest clinical trial repository – and also learn about the latest in survivorship research.

We are exploring fresh areas outside of classic medical oncology drug testing. Three special symposia – on palliative care, translational medicine, and radiation research – will showcase key issues and opportunities for our group. The events are designed to spark discussion and debate. Those conversations will help me and my leadership team set the research agenda for years to come.



SWOG's future is so bright. We're running high-impact trials and publishing important results. Our membership is growing. We've got our biggest, best group of patient advocates, and we're launching exciting digital projects – including a new web site by year's end.

Thank you for your pursuit of excellence, and your commitment to SWOG. Let's get ready for a great meeting. See you soon.

*Charles Blum*

# Group Meeting Index

Plenary Sessions .....	4, 15 & 16	Genitourinary Committee .....	17 & 46-49
The Hope Foundation .....	5 & 19	Imaging Committee .....	16
Trial-Specific Sessions .....	6 & 7	Leukemia Committee .....	17 & 50-53
CME Credit Information .....	8 & 9	Lung Committee .....	15 & 54-57
Group Meeting Supporters .....	9 & 70	Lymphoma Committee .....	17 & 58-59
Hyatt Regency Travel and Hotel Information and Hotel Maps .....	11-13	Melanoma Committee .....	16 & 60-62
Schedule of Events .....	14-17	Patient Advocate Committee .....	14 & 15
Committee Information:		Pharmaceutical Sciences Committee .....	17
Adolescent and Young Adult (AYA) Committee .....	15	Prevention & Epidemiology Committee .....	15 & 34
Barlogie-Salmon Myeloma Committee .....	16 & 22-23	Publications Committee .....	16
Breast Committee .....	17 & 24-27	Radiation Oncology Committee .....	17 & 21
Board of Governors .....	17	Surgery Committee .....	7 & 16
Bone Marrow & Stem Cell Transplantation Committee .....	16	Symptom Control & Quality of Life Committee .....	15 & 35-37
Cancer Care Delivery Committee .....	16 & 30-32	Jeri and Noboru Oishi Symposium .....	14
Cancer Survivorship Committee .....	14 & 33	Oncology Research Professionals (ORP) Open Forum .....	15
Committee Chairs .....	17	Administrative Committees .....	18
Digital Engagement Committee .....	15	Future Group Meeting Dates .....	18
Early Therapeutics & Rare Cancers Committee .....	15 & 38-40	Special Symposia & Events .....	20-21
Gastrointestinal Committee .....	17 & 41-45	SWOG Publications .....	63-69





## Plenary Part I

The spring meeting's Translational Medicine Plenary will take place Thursday, April 27, 3:00-4:30 p.m. in the Grand Ballroom. Speakers and topics will include the following:

### Introductory Comments



**Lee M. Ellis, M.D.**  
SWOG Vice Chair for Translational Medicine  
University of Texas M.D. Anderson Cancer Center

### Lessons Learned from a Decade of Precision Medicine: Where Do We Go From Here?



**Lillian Siu, M.D.**  
Professor of Medicine and Senior Medical Oncologist  
University of Toronto Princess Margaret Cancer Centre

### Combination Immune Therapy



**Mario Sznol, M.D.**  
Professor of Medicine and Co-Director, Yale SPORE in Skin Cancer  
Yale School of Medicine Yale Cancer Center

### Team Science in the New Era of Cancer Research and Translational Medicine



**Margaret Foti, Ph.D., M.D. (hc)**  
Chief Executive Officer  
American Association for Cancer Research

## Plenary Part II

The spring meeting's General Plenary will take place Friday, April 28, 12:00-2:00 p.m. in the Grand Ballroom.

### Chair's Welcome and Update



**Charles D. Blanke, M.D.**  
SWOG Chair  
Oregon Health & Science University

### Innovation in SWOG Treatment Trials



**Julie Gralow, M.D.**  
SWOG Executive Officer  
University of Washington School of Medicine



**Christopher Ryan, M.D.**  
SWOG Executive Officer  
Oregon Health & Science University



**Susan O'Brien, M.D.**  
SWOG Executive Officer  
University of California Irvine

### Innovation in Survivorship Research



**Linda House, R.N., B.S.N., M.S.M.**  
President  
Cancer Support Community

### Innovation at ClinicalTrials.gov



**Deborah Zarin, M.D.**  
Director  
ClinicalTrials.gov  
National Institutes of Health

# Making A Better Meeting

*"The Hope Foundation has been essential to our efforts to bring the best science to the SWOG group meetings, SWOG collaborations with our partner institutes, and ultimately into SWOG studies, where science forms the foundation for better and more innovative clinical trials."*

Dr. Lee M. Ellis,  
SWOG Vice Chair for Translational Medicine

Hope helps members – and leading experts – get to group meetings. Hope also recruits the meeting sponsors, and supports special events and training programs that power a great gathering.

Giving is easier than ever.  
Text "SWOG" to 41444  
to donate online now!

## THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*

Johanna (Jo) Horn, President & CEO | [info@thehopefoundation.org](mailto:info@thehopefoundation.org) | (734) 998-6888 | [www.thehopefoundation.org](http://www.thehopefoundation.org)

# San Francisco Trial-Specific Sessions

## S1605 Kick Off Meeting

### Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Come hear about S1605, a new SWOG immunotherapy trial for bladder cancer. This high-impact trial will provide FDA approval data on atezolizumab, an immune checkpoint inhibitor for patients with bladder cancer whose disease is unresponsive to treatment with BCG.

Friday, April 28 | 9:30-11:30 a.m. | Pacific DE (Pacific Concourse Level)  
Open to All Members; Suggested for Site Staff

*Study Chairs Dr. Peter Black of the University of British Columbia and Dr. Parminder Singh of Mayo Clinic and the study team will discuss the trial design, endpoints, eligibility, audits, central monitoring and regulatory requirements. Attendance is encouraged for sites activating S1605, and staff will receive credit for participating.*

*S1605 will determine if atezolizumab, a new PD-L1 inhibitor, helps patients – saving their bladders and, perhaps, their lives. Last year, 76,960 new cases of bladder cancer were diagnosed in the United States, and thousands need an alternative to BCG.*





## S0820/PACES Update Meeting

**A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)**

**Friday, April 28 | 10:00 a.m. – 11:00 a.m.**  
**Pacific M (Pacific Concourse Level)**  
**Open to All Members**

*Study Co-Chair Dr. Jason Zell of UC Irvine Health and the S0820/PACES study team will provide background on the recently amended protocol, which is now a two-arm trial. They'll share accrual data and recruitment materials and answer questions. Light refreshments will be served.*

Colorectal cancer survivors are at risk of developing a secondary cancer in their colons, or getting high-risk adenomas, benign tumors that can become malignant. This study is being done to determine if these drugs can prevent tumor growth.

## S1316 Update Meeting

**Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction**

**Thursday, April 27 | 5:30 – 6:30 p.m.**  
**Pacific F (Pacific Concourse Level)**  
**Open to All Members**

*Study Chair Dr. Robert Krouse of the Veterans Affairs Medical Center of Philadelphia and the S1316 study team will be available to answer questions. Dr. Virginia Sun of City of Hope will make a presentation on palliative care and Dr. Cynthia Thomson of the University of Arizona Cancer Center will discuss the status of the dietary calls.*

Malignant bowel obstruction is a common problem for patients with advanced abdominal or pelvic cancers. This study is being done to determine whether surgery will improve these patients' quality of life.

## Surgical Complications

**Educational Session: Surgery Committee**

**Friday, April 28, 2017 | 9:00 – 11:00 a.m. | Bayview A (Bay Level)**

**Update: S1505 - neoadjuvant therapy for resectable pancreas cancer**

*Syed A. Ahmad, MD, FACS  
Professor of Surgery  
Chief Division Surgical Oncology,  
The University of Cincinnati  
Medical Center*

**Surgical Complications: Implications Public Rating and Reimbursement**

*George H. Yoo, MD, FACS  
Professor of Otolaryngology  
Wayne State University*

**Future of Surgical Quality**

*Emily Esham  
Advisory Board*

**Surgical Complications and Oncologic Outcome.**

*Claudius Conrad, MD, PhD, FACS  
Department of Surgical Oncology,  
MD Anderson Cancer Center*

# We're now on Facebook


We've launched a private Facebook group — **SWOG Oncology** — to create an online meeting place for every **SWOG** member.

Join the group and you'll get news from **SWOG** and funding alerts from **The Hope Foundation**. You can also talk clinical trial triumphs and troubleshooting, picking up best practices and getting advice on study challenges.

It's easy to sign up.

Log onto Facebook, search for "**SWOG Oncology**" and hit the green "**Join Group**" button. You'll get a notification when your access is approved.

**SWOG**  Leading cancer research. **Together.**



## Tweet the meeting

Tag your group meeting tweets with  
**#swogonc**

We'll post the live stream of tagged group meeting updates to the SWOG website, for ease of following by those who couldn't make it.

Follow SWOG at [twitter.com/SWOG](https://twitter.com/SWOG).

Our username is **@SWOG**.





# San Francisco Travel & Hotel Information

**Hyatt Regency San Francisco | Embarcadero Center | San Francisco, CA 94111 | Phone: 415-788-1234 | Fax: 415-981-3638**



## Arrival/Departure:

Check-in time is 3:00 p.m. Check-out time is 12:00 noon. Room amenities include a full bath, hair dryer, ironing board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.

## Hotel Safety Deposit Boxes:

For your convenience, safety deposit boxes are available at the front desk for your valuables. Please do not leave valuables in your room.

## Recreational Facilities:

The fitness center offers a variety of exercise equipment, free weights, treadmills, and more, exclusively for hotel guests. It is open 24 hours a day.

## Hotel Restaurants and Lounges:

- Eclipse Restaurant specializes in a variety of cuisines and offers guests a relaxing atmosphere to enjoy breakfast, lunch and dinner.
- Eclipse Lounge specializes in a wide variety of cocktails, wines, beers and cognacs.
- In-room dining is available from 6:00 a.m. - 12:00 a.m. daily.

## Business Center:

The Business Center is located on the Atrium Lobby level of the hotel. It is open 24 hours a day, 7 days a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access and photo-copying.

## Ground Transportation:

- A taxi ride from San Francisco airport to the hotel is approximately \$35.00 one-way.
- Valet parking at the hotel is \$50.00 per day for hotel guests.

## Temperature:

The average high for April is 65 degrees and the average low is 50 degrees.

## Area Attractions:

- Alcatraz and Angel Island • Aquarium of the Bay
- Bay Ferry Tours
- Boudin Bakery
- Cable Car Museum
- Coit Tower
- Embarcadero Center
- Farmer's Market
- Ferry Building Marketplace
- Fisherman's Wharf (Pier 39)
- Ghirardelli Square
- Golden Gate Bridge and Park
- Lombard Street
- Napa/Sonoma Wine Country
- San Francisco Maritime National Historical Park • Sausalito Island
- The Exploratorium
- Yerba Buena Center for the Arts
- Yerba Buena Gardens


## Local Restaurants:

(The hotel concierge can assist with reservations and suggestions)

- Alioto's - *Seafood*
- Barney's Gourmet Hamburgers - *Burgers*
- Boudin at the Wharf - *Deli Cuisine* • Caffè Macaroni - *Italian*
- E'Angelo Restaurant - *Italian*
- Harris' - *Steaks/Chops*
- Michael Mina - *American*
- One Market - *American Regional* • Plump Jack Cafe - *Eclectic*
- Tadich Grill - *Steak and Seafood* • The Waterfront - *Seafood*

# Hyatt Regency San Francisco Floor Levels



Embarcadero Center | San Francisco, CA 94111 | Phone: 415-788-1234 | Fax: 415-981-3638





# Hyatt Regency San Francisco Meeting Rooms

Embarcadero Center | San Francisco, CA 94111 | Phone: 415-788-1234 | Fax: 415-981-3638



# Schedule of Events

## Wednesday, April 26, 2017

**Group Meeting Registration & Information Desk**  
1:00 p.m. - 5:00 p.m. - Grand Foyer, Street Level

12:00 P.M. - 2:00 P.M.

**Regency B, Street Level**      Core Office Staff Meeting (Invitation Only)

1:00 P.M. - 3:00 P.M.

**Plaza Room, Street Level**      Nursing Research Subcommittee

2:00 P.M. - 3:00 P.M.

**Seacliff B, Bay Level**      ORP Liaison Subcommittee (Formerly  
Disease & Discipline & Research)

2:00 P.M. - 3:00 P.M.

**Pacific BC, Pacific Level**      SWOG Tissue Banking Meeting  
(Invitation Only)

3:00 P.M. - 5:30 P.M.

**Pacific G, Pacific Level**      ORP Executive Committee (Committee  
Members Only)

3:30 P.M. - 5:00 P.M.

**Regency B, Street Level**      Hope Foundation Board Meeting (Board  
Members Only)

4:00 P.M. - 5:00 P.M.

**Pacific F, Pacific Level**      Task Force on Palliative Medicine and  
ACP/EOL Activities (Open Session)

5:30 P.M. - 7:30 P.M.

**Seacliff CD, Bay Level**      Site Operations (Formerly Head CRA) –  
Open Session

5:30 P.M. - 8:00 P.M.

**Seacliff A, Bay Level**      NCORP Research Base Executive  
Committee Meeting (Cmte Mem Only)

6:30 P.M. - 8:30 P.M.

**Pacific L, Pacific Level**      ITSC Steering Committee (Committee  
Members Only)

## Thursday, April 27, 2017

**Group Meeting Registration & Information Desk**  
7:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Hope Foundation Information Desk**  
8:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Exhibits & Complimentary Coffee Service**  
7:00 a.m. - 4:00 p.m. - Grand Foyer, Street Level

6:00 A.M. - 7:30 A.M.

**Grand Foyer, Street Level**      Conference Fun Run & Walk

7:00 A.M. - 8:00 A.M.

**Seacliff D, Bay Level**      Advocates Committee Meeting  
(Committee Members Only)

7:30 A.M. - 8:00 A.M.

**Grand Foyer, Street Level**      Jeri & Noboru Oishi Symposium Check-In

8:00 A.M. - 8:30 A.M.

**Grand BC, Street Level**      Nurse/CRA Committee Orientation /  
Business Meeting (Open Session)

8:30 A.M. - 12:00 P.M.

**Grand BC, Street Level**      Jeri & Noboru Oishi Symposium (Open  
Session)

8:00 A.M. - 10:00 A.M.

**Bayview B, Bay Level**      Cancer Survivorship Committee

8:00 A.M. - 10:00 A.M.

**Pacific I, Pacific Level**      Lung-MAP Site Coordinators Committee  
(Committee Members Only)

9:00 A.M. - 10:30 A.M.

**Pacific F, Pacific Level**      AstraZeneca Leadership Meeting  
(Cmte Chairs and Invited Guests Only)

10:00 A.M. - 12:00 P.M.

**Plaza Room, Street Level**      Quality Initiative Meeting (Committee  
Members Only)



# Schedule of Events

## Thursday, April 27, 2017

**Group Meeting Registration & Information Desk**  
7:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Hope Foundation Information Desk**  
8:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Exhibits & Complimentary Coffee Service**  
7:00 a.m. - 4:00 p.m. - Grand Foyer, Street Level

10:00 A.M. - 12:00 P.M.

**Pacific K, Pacific Level**      Digital Engagement Committee  
(Committee Members Only)

10:00 A.M. - 12:00 P.M.

**Marina Room, Bay Level**      S1415CD Study Meeting

10:00 A.M. - 12:15 P.M.

**Seacliff A-C, Bay Level**      Early Therapeutics & Rare Cancers Cmte

10:15 A.M. - 12:15 P.M.

**Bayview B, Bay Level**      Symptom Control & Quality of Life  
Committee

12:00 P.M. - 2:00 P.M.

**Bayview A, Bay Level**      Adolescent and Young Adult (AYA)  
Committee

12:30 P.M. - 2:00 P.M.

**Pacific NO, Pacific Level**      ORP Open Forum

12:30 P.M. - 2:30 P.M.

**Bayview B, Bay Level**      Prevention & Epidemiology Committee

12:30 P.M. - 2:30 P.M.

**Pacific DE, Pacific Level**      Lung Working Group (Working  
Group Members Only)

1:00 P.M. - 3:00 P.M.

**Pacific LM, Pacific Level**      Breast Working Group Meeting (Working  
Group Members Only)

2:00 P.M. - 3:00 P.M.

**Grand Foyer, Street Level**      Plenary Reception (Desserts and Coffee)

2:00 P.M. - 3:00 P.M.

**Seacliff B, Bay Level**      ORP Education Subcommittee

3:00 P.M. - 4:30 P.M.

**Seacliff D, Bay Level**      Advocates Committee Meeting  
(Committee Members Only)

3:00 P.M. - 4:30 P.M.

**Grand, Street Level**      Plenary I (Translational Medicine)

4:30 P.M. - 7:30 P.M.

**Pacific BC, Pacific Level**      Myeloma Working Group Meeting  
(Working Group Members Only)

4:45 P.M. - 7:45 P.M.

**Bayview Room, Bay Level**      Lung Committee

5:00 P.M. - 7:00 P.M.

**Plaza Room, Street Level**      Conflict Management Committee  
(Committee Members Only)

5:30 P.M. - 6:30 P.M.

**Pacific F, Pacific Level**      S1316 Protocol Update Meeting

6:00 P.M. - 8:15 P.M.

**Seacliff A-D, Bay Level**      Translational Medicine Retreat on  
Biomarkers for Immune Therapy

8:15 P.M. - 9:00 P.M.

**Marina Room, Bay Level**      Translational Medicine Retreat Breakout  
(Invitation Only)

7:00 P.M. - 8:30 P.M.

**Garden A, Atrium Level**      SWOG Latin America Symposium  
(Invitation Only)

7:30 P.M. - 9:30 P.M.

**Board Room B, Atrium Level**      Coltman Fellowship Committee  
(Committee Members Only)

# Schedule of Events

## Friday, April 28, 2017

**Group Meeting Registration & Information Desk**  
7:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Hope Foundation Information Desk**  
8:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Exhibits & Complimentary Coffee Service**  
7:00 a.m. - 4:00 p.m. - Grand Foyer, Street Level

7:30 A.M. - 9:30 A.M.

**Garden Room, Atrium Level** Cancer Care Delivery Committee

7:30 A.M. - 9:30 A.M.

**Seacliff A-C, Bay Level** Barlogie-Salmon Myeloma Committee

7:30 A.M. - 9:30 A.M.

**Marina Room, Bay Level** Melanoma Working Group Meeting  
(Working Group Members Only)

7:30 A.M. - 9:30 A.M.

**Plaza Room, Street Level** Imaging Committee (Committee Members Only)

7:30 A.M. - 9:30 A.M.

**Board Room A, Atrium Level** SWOG Data and Safety Monitoring Committee (Committee Members Only)

8:00 A.M. - 9:00 A.M.

**Board Room C, Atrium Level** Professional Review Committee (Committee Members Only)

8:00 A.M. - 10:00 A.M.

**Waterfront C, Atrium Level** Drug Information Subcommittee (Working Group Members Only)

9:00 A.M. - 11:00 A.M.

**Pacific L, Pacific Level** Breast Translational Medicine Working Group (Working Group Members Only)

9:00 A.M. - 11:00 A.M.

**Bayview A, Bay Level** Surgery Committee

9:30 A.M. - 11:30 A.M.

**Bayview B, Bay Level** Melanoma Committee

9:30 A.M. - 11:30 A.M.

**Pacific DE, Pacific Level** GU Kick-Off Meeting for S1605

9:45 A.M. - 11:45 A.M.

**Seacliff A-C, Bay Level** Symposium on Palliative Care and Advanced Care Planning: An Unmet Need

10:00 A.M. - 11:00 A.M.

**Pacific M, Pacific Level** S0820 PACES Protocol Update Meeting

10:00 A.M. - 11:30 A.M.

**Pacific C, Pacific Level** Quality Assurance Committee Meeting (Committee Members Only)

10:30 A.M. - 12:00 P.M.

**Pacific J, Pacific Level** Bone Marrow & Stem Cell Transplantation Committee

11:00 A.M. - 12:00 P.M.

**Plaza Room, Street Level** Publications Committee (Committee Members Only)

11:00 A.M. - 12:00 P.M.

**Grand Foyer, Street Level** Plenary Reception (Light Hors D'oeuvres)

12:00 P.M. - 2:00 P.M.

**Grand, Street Level** Plenary II (General)

2:00 P.M. - 4:00 P.M.

**Pacific HI, Pacific Level** Leukemia Working Group Meeting (Working Group Members Only)

2:15 P.M. - 3:15 P.M.

**Pacific L, Pacific Level** NCORP PI Meeting

2:30 P.M. - 3:30 P.M.

**Board Room C, Atrium Level** VA Working Group (Committee Members Only)



# Schedule of Events

## Friday, April 28, 2017

**Group Meeting Registration & Information Desk**  
7:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Hope Foundation Information Desk**  
8:00 a.m. - 5:00 p.m. - Grand Foyer, Street Level

**Exhibits & Complimentary Coffee Service**  
7:00 a.m. - 4:00 p.m. - Grand Foyer, Street Level

2:30 P.M. - 4:00 P.M.

**Seacliff A-D, Bay Level** S1400 Lung-MAP Update Meeting

2:30 P.M. - 4:30 P.M.

**Marina Room, Bay Level** GI Working Group Meeting (Working Group Members Only)

2:30 P.M. - 6:30 P.M.

**Pacific JK, Pacific Level** GU Organ Site Meeting (Working Group Members Only)

3:00 P.M. - 5:00 P.M.

**Golden Gate, Bay Level** ORP Planning Meeting (Committee Members Only)

3:00 P.M. - 6:00 P.M.

**Grand A, Street Level** Breast Committee

3:30 P.M. - 5:00 P.M.

**Pacific D, Pacific Level** Film Screening: Patient: A Surgeon's Journey

4:00 P.M. - 6:00 P.M.

**Pacific C, Pacific Level** Recruitment and Retention Committee Meeting

4:00 P.M. - 6:00 P.M.

**Bayview B, Bay Level** Leukemia Committee

4:00 P.M. - 6:00 P.M.

**Pacific HI, Pacific Level** Lymphoma Working Group (Working Group Members Only)

4:30 P.M. - 6:30 P.M.

**Board Room B, Atrium Level** Pharmaceutical Sciences Committee

5:00 P.M. - 7:00 P.M.

**Grand C, Street Level** GI Committee

6:00 P.M. - 7:00 P.M.

Executive Reception (Invitation Only)

6:45 P.M. - 8:00 P.M.

**Atrium, Atrium Level** Reception

## Saturday, April 29, 2017

**Group Meeting Registration & Information Desk**  
7:00 a.m. - 11:00 a.m. - Grand Foyer, Street Level

**Hope Foundation Information Desk**  
8:00 a.m. - 11:00 a.m. - Grand Foyer, Street Level

7:15 A.M. - 8:00 A.M.

**Grand B, Street Level** Board of Governors (Board Members Only)

8:15 A.M. - 9:15 A.M.

**Grand B, Street Level** Committee Chairs (Committee Chairs Only)

9:00 A.M. - 1:00 P.M.

**Bayview B, Bay Level** Strategic Planning Symposium for Radiation Research in SWOG

9:30 A.M. - 12:30 P.M.

**Grand C, Street Level** Lymphoma Committee

9:30 A.M. - 12:30 P.M.

**Grand A, Street Level** GU Committee

12:30 P.M. - 8:30 P.M.

**Marina Room, Bay Level** Leadership Academy (Invitation Only)

# SWOG Administrative Committees

## **Adolescent & Young Adults**

**Chair:** Mark A. Lewis, M.D.

## **Board of Governors**

**Chair:** Charles D. Blanke, M.D.

## **Bone Marrow and Stem Cell Transplantation**

**Chair:** Patrick J. Stiff, M.D.

## **Conflict Management**

**Chair:** Paul Okunieff, M.D.

## **Data & Safety Monitoring**

**Chair:** Lawrence E. Flaherty, M.D.

## **Digital Engagement**

**Chair:** Don S. Dizon, M.D.

## **Imaging**

**Chair:** Lawrence H. Schwartz, M.D.

## **Oncology Research Professionals**

**Chair:** Keisha Humphries, R.N., B.S.N.

## **Patient Advocates**

**Chair:** Rick Bangs, M.B.A.

## **Pharmaceutical Sciences**

**Co-Chair:** Siu-Fun Wong, Pharm.D.

**Co-Chair:** Susan Kadlubar, Ph.D.

## **Publications**

**Chair:** Hagen Kennecke, M.D.

## **Professional Review**

**Chair:** Primo N. Lara, Jr., M.D.

## **Quality Assurance**

**Chair:** Manuel Valdivieso, M.D.

## **Radiation Oncology**

**Chair:** Paul Okunieff, M.D.

## **Recruitment & Retention**

**Chair:** Elise Cook, M.D.

## **Surgery**

**Chair:** George H. Yoo, M.D.

## **Future Meeting Dates**

### **2017**

Oct 11-14  
Chicago, IL

### **2018**

April 11-14  
San Francisco, CA

Oct 3-6  
Chicago, IL

### **2019**

April 24-27  
San Francisco, CA

Oct 2-5  
Chicago, IL

### **2020**

April 22-25  
San Francisco, CA

Sep 23-26  
Chicago, IL



# THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*

**The Hope Foundation provided \$3,039,334 in charitable funding to SWOG and its members for group meetings, research, training and travel, including individual research grants and training support to 181 members**

“

The foundation in 2016 rolled out a host of new programs that offered more research grants and more training dollars directly to SWOG members.



Johanna R. Horn,  
President & CEO,  
The Hope Foundation

Thanks to board guidance and a stellar team, we navigated challenges with an efficiency and focus that had measurable impact on SWOG's mission.

”

A handwritten signature in white ink, appearing to read 'JRH', located below the quote on the right side of the page.

# San Francisco Special Events

## Palliative Care Symposium

**Friday, April 28 | 9:45 - 11:45 a.m. | Seacliff A-C (Bay Level)**

### Open to All Members

Four speakers will share their expertise in clinical care delivery models, medical ethics, oncology faculty training, and palliative care interventions. The agenda will highlight patient-physician communication, advanced care planning, and more. The long-term goal of this event is development of a research program to address palliative care within SWOG and NCI's National Clinical Trials Network.

### Speakers will include:

**Anthony Back, MD,**  
Professor, Department of Medicine,  
University of Washington

**Christine Richie, MD, MSPH,**  
Professor of Medicine,  
University of California San Francisco

**Amy Vandenbroucke, JD,**  
Executive Director,  
National POLST Paradigm

**Marie Bakitas, DNSc, NP-C, FAAN,**  
Professor, Marie O'Koren Endowed Chair,  
Associate Director, Center for Palliative  
and Supportive Care, The University of  
Alabama at Birmingham



## Bonus Event!

### Free Movie Screening

**Friday, April 28 | 3:30 p.m.**

**Pacific D (Pacific Concourse Level)**

### Open to All Members

Come see *Patient, A Surgeon's Journey*, an end-of-life documentary on the late Dr. Jeffrey Piehler, a Kansas surgeon grappling terminal prostate cancer.



<< SWOG member Dr. Peter Van Veldhuizen appears in the film, worked on the production, and will speak at the screening.

# Translational Medicine Mini-Retreat

**Thursday, April 27 | 6:00 - 8:05 p.m. | Seacliff A-C (Bay Level)**

## Open to All Members/Registration Required

A series of short talks organized by Mario Sznol, MD, of Yale Cancer Center, Karolina Palucka, MD, PhD, of The Jackson Laboratory, and Mikala Egeblad, PhD, of Cold Spring Harbor Laboratory.

### Speakers and topics include:

- **Introduction and Welcome**  
Lee M. Ellis, MD, SWOG Vice-Chair for Translational Medicine, MD Anderson Cancer Center
- **FDA Blueprint Project: Comparing Current Used PD-L1 assays**  
Fred Hirsch, MD, University of Colorado
- **Multiplexed Quantitative Immune-Profilng in Tumor Tissues**  
Kurt Schalper, MD, PhD, Yale School of Medicine
- **Beyond Expression Level: How Spatial Relationships Between Cells and Biomarkers Add to Predictive/Prognostic Value**  
Paul Tumeh, MD, Acteris
- **Multi-Parametric Biomarker Program from Genentech**  
Priti Hegde, PhD, Genentech
- **The Merck Gene Expression Profile in Predicting Response to Anti-PD1**  
David Kaufman, MD, PhD, Merck
- **CIBERSORT and Computational Approaches to Unravel Genomic Data for Immune Markers**  
Aaron Newman, PhD, Stanford University
- **Is All the Information in the Tumor Cell? Mutation and Pathway Analyses as Predictive Biomarkers**  
Roger Lo, MD, PhD, UCLA David Geffen School of Medicine
- **Is All the Information in the T-Cell Infiltrate? TCR and Activation Analyses of Tumor T-Cell Infiltrates**  
Larry Fong, MD, UCSF Helen Diller Family Comprehensive Cancer Center

# Radiation Oncology Symposium

**Saturday, April 29 | 9:00 a.m. - 1:00 p.m. | Bayview B (Bay Level)**

This session will focus on strategic planning for radiation research in SWOG, and was organized by the SWOG radiation oncology strategic planning subcommittee.

### Speakers and topics include:

#### Clinical Trial Designs

Heiko Enderling, PhD,  
Moffitt Cancer Center

James Welsh, MD, MD  
Anderson Cancer Center

Parminder Singh, MD,  
Mayo Clinic Arizona

#### Translational Research

Martin Brown, PhD,  
Stanford University

Paul Okunieff, MD, Chair of  
SWOG Radiation Oncology  
and Conflict Management

#### Biological Modifiers and Targeted Therapies

Robert Bristow, MD, PhD,  
University of Toronto

Paul Spellman, PhD, Oregon  
Health & Science University

#### Diagnostic Imaging and Biomarkers

Susan Knox, MD,  
Stanford University

Charles Manning, PhD,  
Vanderbilt University

Felix Feng, MD,  
University of California,  
San Francisco

#### Industry

Susan Galbraith, MD, PhD,  
AstraZeneca

Steven Finkelstein, MD,  
Enterade



# Barlogie-Salmon Myeloma Committee

## Leadership

Chair: ..... Robert Z. Orlowski, M.D., Ph.D.  
 Vice-Chair: ..... Brian G.M. Durie, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Antje Hoering, Ph.D.  
 ..... Rachael Sexton, M.S.  
 ..... Kari Chansky, M.S.

## Scientific Leadership

Translational Medicine: ..... Joshua Epstein, D.Sc.  
 Radiation: ..... TBD  
 Surgery: ..... J. Sybil Biermann, M.D.  
 Imaging: ..... Saad Z. Usmani, M.D.  
 ..... Eric M. Rohren, M.D., Ph.D.  
 Pathology: ..... Robert B. Lersbach, M.D., Ph.D.  
 Early Therapeutics: ..... Frits van Rhee, M.D., Ph.D.

## Designates

NCORP Representative: ..... George F. Geils, Jr., M.D.  
 Data Coordinators: ..... Jeri Jardine  
 ..... Laura Kingsbury, M.R.T.  
 ..... Sean O'Bryan  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Deborah A. Shaw, R.N.  
 ..... Teresa Wtcher, B.S.N., R.N.  
 Patient Advocate: ..... Jack Aiello  
 Pharmaceutical Science: ..... Lara M. Au, Pharm.D.  
 ..... Craig Elg, Pharm.D.  
 Protocol Coordinator: ..... Cara Laubach

## Time/Location

Friday, April 28, 2017 7:30 a.m. - 9:30 a.m.  
 Room: Seaclyff A-C (Bay Level)

## Active Studies

**S1211**, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. Usmani, Ailawadhi, and Shah. Activated: 10/12/12. Temporarily closed to accrual: 6/2/16.

**CTSU/E3A06**, "Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma." Dr. Dhodapkar. Activated by ECOG: 10/5/10; Activated by SWOG: 2/1/11.

**CTSU/E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide

and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Dr. Zonder. Activated by ECOG: 11/13/13; Activated by SWOG: 2/1/14.

**CTSU/A061402**, "Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy." Dr. Manasanch. Pre-Activated by SWOG: 11/15/16; Activated by Alliance: 12/23/15.

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Dr. Villalobos. Activated by Alliance and SWOG: 8/12/15.

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immuno-deficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13.

## Closed Studies

**S1304**, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease." Drs. Ailawadhi, Abidi, Lentzsch, Orlowski, and Rohren. Activated: 10/18/13. Closed: 5/15/16.

## Proposed Studies

**S1611**, "A Phase II Non-Randomized Study of 11-1F4 Chimeric Monoclonal Ab added to standard treatment in Untreated Subjects with Light Chain (AL) Amyloidosis." Dr. Lentzsch.

**S1702**, "A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis." Dr. Scott.

**S1710**, "Randomized Phase II Multicenter Non-Inferiority Trial of Rivaroxaban 10 mg Daily Versus Low Molecular Weight Heparin for Prevention of Thromboembolism in Patients Being Treated with an Immunomodulatory-Based Regimen for Multiple Myeloma." Drs. Calverley, Meyers, and Scott.

**SXXXX**, "A Phase I/II Study in Patients with Relapsed/Previously Treated Waldenström's Macroglobulinemia (WM)." Dr. Ailawadhi.

**SXXXX**, "Randomized Phase III Study of Lenalidomide (L) vs. Lenalidomide + Ixazomib (NSC-767907) (LI) as Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma (MM)." Dr. Shah.

## Open Forum Discussion & Working Groups

# Barlogie-Salmon Myeloma Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1211	S1304	E1A11	E3A06
Arizona MC, U of	—	1	—	—
Arkansas, U of	—	—	1	—
Baylor College	—	—	5	—
Beaumont NCORP	—	—	4	—
Boston MC MBCCOP	—	1	—	—
Boston Medical Ctr	—	1	—	—
CORA NCORP	—	—	1	—
CRC West MI NCORP	1	—	—	—
City of Hope Med Ctr	7	—	—	—
Cleveland Clinic OH	10	—	—	—
Columbus NCORP	4	—	—	—
Cookeville Reg MC	—	—	2	—
Davis, U of CA	—	2	4	—
Dayton NCORP	1	—	2	—
Essentia Hlth NCORP	1	—	—	—
Greenville NCORP	—	—	—	6
Hawaii MU-NCORP	—	—	1	—
Heartland NCORP	3	4	—	—
Henry Ford Hosp	—	—	4	1
Irvine, U of CA	—	—	4	1
Kaiser Perm NCORP	—	10	12	—
Kansas City NCORP	1	—	—	—
Kansas, U of	13	—	1	15
Lahey Hosp & Med Ctr	—	1	—	—
Loyola University	3	5	3	—
MD Anderson CC	10	7	—	—
Michigan CRC NCORP	5	8	—	—
Mississippi, Univ of	—	1	—	—
Montana NCORP	—	2	3	2
Nevada CRF NCORP	—	2	—	—
Northwest NCORP	—	1	—	—
Oklahoma, Univ of	1	1	—	—
Oregon Hlth Sci Univ	—	—	3	—
Ozarks NCORP	2	1	6	1
PCRC NCORP	—	—	—	1
Providence Hosp	4	4	4	1
Rochester, Univ of	7	—	—	—
San Antonio, U of TX	15	—	3	—
So Calif, U of	2	17	—	—
Southeast COR NCORP	4	3	3	—
Sutter Cancer RC	—	—	5	—
Tennessee, U of	—	—	—	1
Tulane University	1	—	—	2
VAMC Kansas City	—	—	1	—
Wayne State Univ	3	—	8	—
Wichita NCORP	—	1	—	—
Yale University	—	7	11	2
Alliance	10	33	—	—
ECOG-ACRIN	31	21	—	—
NRG	3	9	—	—
<b>Total</b>	<b>142</b>	<b>143</b>	<b>91</b>	<b>33</b>

# Breast Committee

## Leadership

Chair: ..... Gabriel N. Hortobagyi, M.D.  
 Vice-Chair: ..... Debasish Tripathy, M.D.  
 Executive Officer: ..... Julie R. Gralow, M.D.  
 Statisticians: ..... William E. Barlow, Ph.D.  
 ..... Danika Lew, M.A.  
 ..... Jieling Miao, M.S.

## Scientific Leadership

Translational Medicine: ..... Daniel F. Hayes, M.D.  
 Radiation Oncology: ..... Reshma Jagsi, M.D.  
 Surgery: ..... Christine Lee, M.D.  
 Imaging: ..... Anne F. Schott, M.D.  
 ..... Wei Tse Yang, M.B.B.S.  
 Pathology: ..... Allen M. Gown, M.D.  
 ..... Peggy L. Porter, M.D.  
 Early Therapeutics: ..... George Somlo, M.D.

## Designates

Cancer Control Liaisons: ..... Carol J. Fabian, M.D. (Cancer Survivorship)  
 ..... Dawn L. Hershman, M.D. (Cancer Care Delivery)  
 ..... Banu Arun, M.D. (Prevention)  
 ..... Helen K. Chew, M.D. (Symptom Control & QOL)  
 NCORP Representative: ..... Melanie E. Royce, M.D., Ph.D.  
 Data Coordinators: ..... Iris Syquia  
 ..... Larry Kaye  
 ..... Jacqueline Scurlock  
 ..... Joanna Dur  
 Oncology Research Professionals:  
 CRA: ..... Karyn N. Hart, C.C.R.P.  
 Nurses: ..... Dorothy Coleman, R.N., M.S.  
 ..... Kathy L. Czaplicki, R.N., M.S.N.  
 ..... Crystal L. Watson, R.N.  
 Patient advocates: ..... Ginny Mason, R.N., B.S.N.  
 ..... Elda Railey, R.N., B.S.N.  
 Pharmaceutical Science: ..... Jessie Modlin, Pharm.D.  
 ..... Rivka Siden, Pharm.D.  
 Protocol Coordinator: ..... TBD

## Time/Location

Friday, April 28, 2017 3:00 p.m. - 6:00 p.m.  
 Room: Grand A (Street Level)

## Agenda

**3:00 – 3:05 pm:** Welcome and Introductions – Gabriel Hortobagyi, M.D. and Debu Tripathy, M.D.

**3:05 – 4:00 pm:** Breast Committee Mini-Symposium “ESR1 mutations”

**3:00 – 3:15 pm:** Introduction – Daniel F. Hayes, MD – University of Michigan

**3:15 – 3:35 pm:** Overview of current methods to measure ESR1 mutations. Funda Meric-Bernstam – MD Anderson Cancer Center

**3:35 – 3:50 pm:** Current and future possible SWOG studies: Rae – James Rae, PhD, University of Michigan

**3:50 – 4:05 pm:** Panel discussion and audience Q & A

**4:05 – 4:10 pm:** Publications update - Bill Barlow, Ph.D.

**4:10 – 4:40 pm:** Update of open SWOG and CTSU trials - All

**4:40 – 5:00 pm:** Studies in Development - All

**5:00 – 5:15 pm:** Reports from Committee Liaisons

Radiotherapy - Reshma Jagsi, M.D.

Surgery - Christine Lee, M.D.

Cancer Survivorship - Carol Fabian, M.D.

Cancer Care Delivery - Dawn Hershman, M.D.

Prevention – Banu Arun, M.D.

NCORP (NCI Community Oncology Research Program) – Melanie Royce, M.D.

Patient advocates – Ginny Mason and Elda Railey

**5:15 – 5:25 pm:** Translational Medicine Subcommittee – Daniel Hayes, M.D.

**5:25 – 6:00 pm:** New Business – All

**6:00 pm** Adjourn

## Active Studies

**S1207**, “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.” Drs. Chavez-MacGregor, Rastogi, Pusztai. Activated: 9/3/13.



# Breast Committee

**S1416**, "Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple Negative Breast Cancer (TNBC) and BRCA Mutation-Associated Breast Cancer." Drs. Rodler and Sharma. Activated: 7/7/16.

**S1418**, "A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >1 cm Residual Invasive Cancer or Positive Lymph Nodes (pNmic) After Neoadjuvant Chemotherapy." Drs. Pusztai, Sharma and Mammen. Activated: 11/15/16.

**CTSU/A011106**, "Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study." Dr. Forero. Activated: 12/13/13.

**CTSU/NSABP B-55**, "A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy." Dr. Sharma. Activated: 7/3/14.

**CTSU/E2112**, "A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer." Dr. Royce. Activated: 3/29/14.

**CTSU/EAY 131**, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/15.

## Active Cancer Control Studies

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13.

**S1415CD**, "A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia." Drs. Ramsey, Hershman, Lyman and Sullivan. Activated: 9/1/16.

**CTSU/E1Z11**, "A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)." Dr. Henry. Activated: 5/31/13.

## Closed Studies

**S1007**, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less." Drs. Kalinsky, Gralow, Meric-Bernstam, Hortobagyi, Albain and Barlow. Activated: 1/15/11. Closed: 10/1/15.

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 3/27/12.

**S1202**, "A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer." Drs. Henry and Schott. Activated: 5/15/13. Closed: 10/1/15.

## Studies in Development

**S1411**, "Phase II Randomized Trial of Adjuvant Vaccine Therapy in Patients with High-Risk HER2-Positive Breast Cancer." Dr. Mittendorf.

**S1706**, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Veliparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi.

**S1501**, "Prospective Evaluation of Carvedilol vs No Treatment in Prevention of Cardiac Dysfunction in Women with Metastatic HER2+ Breast Cancer." Drs. Floyd and Leja.

# Breast Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1007	S1207	S1416	A011106	A011202	A011203	A011401	B51	B52	B55	E1Z11	E2108	E2112	E3108	E4112	EA1131	NRGBR003	Z11102
Arizona MC, U of	—	8	—	13	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Arkansas, U of	22	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Atlanta Reg CCOP	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
BC Cancer Agency	—	—	—	—	—	—	—	—	—	—	—	—	—	13	—	—	—	—
Baptist MU-NCORP	1	2	1	9	1	—	—	—	—	—	1	—	1	—	—	—	1	—
Bay Area NCORP	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Baylor Univ Med Ctr	—	2	—	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—
Beaumont NCORP	30	7	—	—	—	—	—	—	—	—	3	5	—	—	—	—	—	1
Brooke Army Med Ctr	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—
CORA NCORP	16	11	—	1	—	—	—	2	—	—	1	1	3	—	—	—	—	—
CRC West MI NCORP	7	3	—	—	—	—	1	—	—	—	2	—	—	—	—	—	—	—
Carle CC NCORP	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	8	9	—	—	—	—	—	—	3	4	—	—	—	—	—	—	—	—
Cincinnati MC, U of	3	7	—	—	—	—	—	—	1	—	4	—	—	—	—	—	—	—
City of Hope Med Ctr	45	14	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
Cleveland Clinic OH	27	11	—	—	—	—	—	—	—	—	—	—	7	—	—	—	3	—
Colorado, U of	29	10	—	—	19	—	1	1	—	1	2	—	—	—	—	—	—	6
Columbia MU-NCORP	16	4	—	—	—	—	—	—	1	—	16	—	2	—	—	—	—	—
Columbia University	2	—	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—
Columbus NCORP	18	11	1	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—
Cookeville Reg MC	7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	8	4	2	—	—	—	—	—	—	—	1	1	—	1	—	—	—	—
Dayton NCORP	6	4	2	—	—	—	1	—	—	—	2	1	—	—	—	—	—	—
Desert Hospital	2	1	—	—	2	—	—	2	—	—	—	—	—	—	—	—	—	—
Essentia Hlth NCORP	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fred Hutchinson CRC	6	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Georgia NCORP	—	1	—	—	—	—	—	—	—	—	8	—	—	—	—	—	—	—
Greenville NCORP	4	—	—	—	—	—	—	—	—	—	12	1	—	—	—	—	—	—
Gulf Coast MBCCOP	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	6	14	—	—	—	—	—	—	—	—	5	1	—	—	—	—	1	—
H Lee Moffitt CC	2	5	—	—	1	—	—	—	—	—	—	1	—	—	11	—	—	—
Harrington CC	2	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Harrison Medical Ctr	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hawaii MU-NCORP	12	6	—	—	—	—	—	—	—	—	13	—	—	1	—	—	—	—
Heartland NCORP	12	14	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Henry Ford Hosp	11	3	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—
INC, Bogota	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
INCan	96	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intermountain MC	5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Irvine, U of CA	21	5	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaiser Perm NCORP	89	25	—	—	1	2	—	—	—	—	27	—	—	—	1	—	—	—
Kansas City NCORP	11	5	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—
Kansas, U of	33	26	—	—	2	—	—	—	1	1	—	—	6	—	—	—	—	—
Kentucky, U of	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
King Faisal Spec Ho	3	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
Lahey Hosp & Med Ctr	19	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Loma Linda Univ	5	5	—	—	1	—	—	1	1	—	—	—	—	—	—	—	—	—

## Breast Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1007	S1207	S1416	A011106	A011202	A011203	A011401	B51	B52	B55	E1Z11	E2108	E2112	E3108	E4112	EA1131	NRGBR003	Z11102
Loyola University	30	7	—	—	—	—	1	1	1	—	—	—	—	—	—	—	—	—
MD Anderson CC	147	41	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
MUSC MU-NCORP	21	5	2	1	—	—	—	—	—	—	5	1	—	—	—	—	—	—
Madigan Army Med Ctr	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Methodist Hospital	7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3
Michigan CRC NCORP	44	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Michigan, U of	29	15	—	—	—	—	—	—	—	1	11	—	—	—	—	—	3	—
Mississippi, Univ of	4	—	—	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—
Montana NCORP	9	6	1	—	—	—	—	—	—	—	4	3	—	—	—	—	—	—
National Cancer Ctr	143	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nevada CRF NCORP	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	27	12	3	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	28	2	—	—	—	—	—	—	—	1	—	3	—	—	—	—	—	—
Northwestern Univ	3	6	—	—	—	4	—	—	—	—	—	—	2	—	—	—	1	—
Oklahoma, Univ of	8	8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Oregon Hlth Sci Univ	4	11	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ozarks NCORP	9	12	1	—	—	—	—	—	—	—	9	—	—	—	—	—	3	—
PCRC NCORP	31	13	—	—	—	—	—	—	—	—	6	6	—	—	—	—	1	—
Providence Hosp	8	6	—	—	2	—	—	1	—	1	2	1	—	—	—	—	3	—
Rochester, Univ of	7	4	—	—	—	—	—	—	—	—	—	4	—	—	—	—	—	—
San Antonio, U of TX	25	18	—	1	—	—	—	—	—	—	—	—	4	—	—	—	3	—
San Diego, U of CA	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1
So Calif, U of	15	5	—	—	2	—	—	—	—	—	—	2	—	—	—	—	—	—
Southeast COR NCORP	31	16	2	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—
St Louis CCOP	3	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
St Louis University	1	1	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	—	9	1	2	—	—	—	1	—	—	—	2	—	—	—	—	2	—
Tennessee, U of	5	4	—	—	1	—	—	1	—	—	—	—	—	—	—	—	—	—
Tulane Univ MBCCOP	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Tulane University	6	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
Univ of Louisville	8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Upstate Carolina	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Utah, U of	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wayne State Univ	23	9	—	—	6	—	—	—	—	2	—	2	2	1	—	—	3	3
Wichita NCORP	57	25	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wisconsin NCORP	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Yale University	24	20	—	—	—	—	7	—	—	—	2	2	—	1	7	—	2	—
Alliance	526	182	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
CCTG	328	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	713	172	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
GEICAM	792	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
NRG	265	206	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
UNICANCER	649	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>4,710</b>	<b>1,079</b>	<b>27</b>	<b>30</b>	<b>41</b>	<b>6</b>	<b>11</b>	<b>10</b>	<b>9</b>	<b>11</b>	<b>138</b>	<b>52</b>	<b>28</b>	<b>17</b>	<b>20</b>	<b>1</b>	<b>26</b>	<b>14</b>



# Cancer Control and Prevention Committees

## Leadership

Vice-Chair NCORP: ..... Dawn L. Hershman, M.D., M.S.\*  
 Cancer Care Delivery Cmte Co-Chairs: .... Dawn L. Hershman, M.D., M.S.\*  
 ..... Scott D. Ramsey, M.D., Ph.D.\*  
 Cancer Survivorship Cmte Co-Chairs: ..... Carol J. Fabian, M.D.\*  
 ..... Robert S. Krouse, M.D., FACS\*  
 Prevention and Epidemiology Cmte Co-Chairs: ..... Banu Arun, M.D.\*  
 ..... Marian Neuhouser, Ph.D., R.D.\*  
 Symptom Control & QOL Cmte Co-Chairs: .... Michael Fisch, M.D., Ph.D.\*  
 ..... Norah Lynn Henry, M.D., Ph.D.\*  
 Executive Officers: ..... Katherine D. Crew, M.D.\*  
 ..... Gary H. Lyman, M.D.\*  
 Senior Advisor: ..... Frank L. Meyskens, Jr., M.D.\*  
 Statisticians: ..... Garnet Anderson, Ph.D.\*  
 ..... William E. Barlow, Ph.D.\*  
 ..... Katherine Guthrie, Ph.D.\*  
 ..... Cathy Tangen, Dr.P.H.\*  
 ..... Joseph M. Unger, Ph.D.\*  
 ..... Kathryn B. Arnold, M.S.\*  
 ..... Amy K. Darke, M.S.\*  
 ..... Phyllis J. Goodman, M.S.\*  
 ..... Danika Lew, M.A.\*  
 ..... Anna Moseley, M.S.\*  
 ..... Cathee Till, M.S.\*  
 Administrative Lead (Statistical Center): ..... Monica Yee, B.A., C.C.R.P.\*

## Scientific Leadership

NCORP Representative: ..... Mark A. O'Rourke, M.D.\*  
 Radiation Therapy Committee: ..... Louis "Sandy" Constine, M.D.  
 Surgery Committee: ..... Robert S. Krouse, M.D.FACS\*  
 Translational Medicine: ..... James (Jimmy) Rae, Ph.D.\*

## Liaisons

Breast Committee: ..... Carol J. Fabian, M.D. (Survivorship)\*  
 ..... Helen K. Chew, M.D. (Symptom Control & QOL)\*  
 ..... Dawn Hershman, M.D., M.S. (CCD)\*  
 ..... Banu Arun, M.D. (Prevention)\*  
 CCDR Committee: ..... Afsaneh Barzi, M.D. (GI Liaison)  
 Gastrointestinal Committee Colon: ..... Jason, Zell, D.O.  
 Genitourinary Committee: ..... Peter J. Van Veldhuizen, Jr., M.D.  
 International Liaison: ..... Kathy S. Albain, M.D.\*  
 Lung Committee: ..... Gary E. Goodman, M.D.\*  
 Lymphoma Committee: ..... TBD  
 Melanoma Committee: ..... Sancy Leachman, M.D., Ph.D.  
 Recruitment and Retention: ..... Elise Cook, M.D.

## Designates

### Oncology Research Professionals:

CRAs: ..... Connie Szczepanek, R.N.  
 ..... Amanda R. Dinsdale, M.H.A., C.C.R.C.  
 ..... Mindy Whisnant, C.C.R.P.

Nurses: ..... Joan Long, R.N.  
 ..... Michaela S. Sherbeck, R.N.  
 ..... Joyce N. Tull, R.N.

Pharmaceutical Science Committee: ..... Manj Randhawa, Pharm.D.  
 ..... Siu-Fun Wong, Pharm.D.\*  
 ..... Susan A. Kadlubar, Ph.D.

### Statistical Center Support and

Data Coordinators: ..... Karen Anderson\*  
 ..... Monica Yee, C.C.R.P.\*  
 ..... Heidi Dong.\*  
 ..... Diane Liggett, C.C.R.P.\*  
 ..... Jennifer Patterson\*

..... Roxanne Topacio, C.C.R.P.\*  
 Patient Advocates: ..... T. Bradley Bott, M.B.A., C.C.R.P. (CCDR)  
 ..... Amy Geschwender, Ph.D. (Symptom Control & QOL)  
 ..... Anna Gottlieb (Survivorship)  
 ..... Sandra Jean Hamilton, R.N., M.E.D. (Recruitment/Retention)  
 ..... Cheryl Jernigan (Prevention & Epidemiology)

### Protocol Coordinators:

Cancer Care Delivery; Prevention &  
 Epidemiology Committees ..... Patricia O'Kane\*  
 Cancer Survivorship Committee: ..... Nicki Trevino\*  
 Symptom Control & QOL Committee: ..... Dawne Wenzel, M.A., M.S.\*

\* Executive Committee Members and Staff

# Cancer Care Delivery Committee

## Leadership

Co-Chairs: ..... Dawn L. Hershman, M.D., M.S.  
 ..... Scott D. Ramsey, M.D., Ph.D.

## Time/Location

Friday, April 28, 2017 7:30 a.m. - 9:30 a.m.  
 Room: Garden Room (Atrium Lobby Level)

## Presentations/Concepts

Mixed Methods and Other New Approaches to Determining Best Practices,  
 Douglas W. Blayney, M.D., Stanford School of Medicine

Drug Interaction Screening Tool for Clinical Trial Enrollment, Dan Hertz,  
 Pharm. D., Ph.D., University of Michigan College of Pharmacy

Optimizing Clinical Work Intensity Among Medical Oncologists, Matthew  
 Hudson, PhD, MPH, Greenville Health System

Ancillary Study to Evaluate Patient & Physician Knowledge, Attitudes,  
 and Preferences Related to Return of Genomic Results in SWOG 1400  
 (Lung-MAP), Josh Roth, PhD, MHA, Fred Hutchinson; Meghna Trivedi, MD,  
 Columbia University

A Pilot Study to Raise Awareness about SWOG Clinical Trials on an Online  
 Oncologist Question and Answer (Q&A) Network, Nadine Housri, MD,  
 Rutgers Robert Wood Johnson Medical School

Cancer Care Delivery Research Scientific Update, Ann Geiger, MPH, PhD, NCI

## Concepts Approved by Triage

**S1705**, "Post Marketing Utilization and Effectiveness of Nivolumab and  
 Palbociclib in General Population." Drs. Barzi and Lyss.

**S1703**, "Randomized trial comparing overall survival of patients monitored  
 with serum tumor marker directed disease monitoring (STMDDM) versus  
 usual care in patients with metastatic hormone receptor positive breast  
 cancer." Dr. Accorino.

## Concepts in Development

Breast Cancer Endocrine Therapy Adherence Text Messaging Study ("BETA-  
 Text"). Dr. Mougalian.

Health Insurance Coverage as a Potential Barrier to Enrollment in Cancer  
 Clinical Trials. Dr. Roth.

## Active Studies

**S1415CD**, "A Pragmatic Trial Assessing Colony Stimulating Factor (CSF)  
 Prescribing Effectiveness and Risk (TRACER)." Drs. Ramsey, Hershman,  
 Lyman, Sullivan, Bansal and Barlow.

**S1417CD**, "Implementation of a Prospective Financial Toxicity Assessment  
 Tool in Patients with Metastatic Colorectal Cancer." Dr. Shankaran.

PCORI Project: A Structured Approach to Prioritizing Cancer Research Using  
 Stakeholders and Value of Information (VOI)

## Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

**S1007**, "Update on Quality of Life and Economic Analysis Sub-study of  
 Breast protocol S1007." Dr. Barlow.

# Let's Make More Time

**SWOG**   
 Leading cancer research. Together.

# Cancer Care Delivery Committee

**S1207.** “Cost Effectiveness Analysis of “Phase III Randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer.” Dr. Chavez-MacGregor.

## Closed Studies

**S1204.** “A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) Among Newly Diagnosed Cancer Patients.” Drs. Ramsey, Loomba, Chugh, Hershman, and Hwang. Activated: 8/29/13. Closed: 2/15/17.

**S1105.** “Randomized Controlled Trial of a Behavioral Intervention to Improve Adherence to Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer”. Drs. Hershman and Neugut.

## Newly Funded And Ongoing Database/Grant Funded Projects

Value of Information and SWOG Trials, PCORI Project. Drs. Ramsey and Carlson.

Long-term Consequences of Intervention Following Receipt of Finasteride or Placebo in the Prostate Cancer Prevention Trial. Dr. Unger.

## Newly Funded Database Studies

Development of Prognostic Risk Models for Response to Treatment and Placebo for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. Dr. Henry.

Secondary Data Analysis of Adolescent & Young Adult Oncology (AYA) Patients in Relation to their Body Mass Index (BMI) and Cancer Outcomes. Dr. Lewis.

## Ongoing Database Pilot Studies

Ethnic disparities among participants in SWOG randomized clinical trials. Dr. Chavez.

Osteoporosis in Patients with Colorectal Cancer Enrolled on SWOG Trials. Dr. Barzi.

Deconstructing the endpoints of SWOG trials. Dr. Prasad.

Evaluating the role of geographic location on outcomes among patients enrolled in SWOG trials. Dr. Symington.





## Cancer Care Delivery Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1204	S1415CD	S1417CD	A011104
Bay Area NCORP	88	—	—	—
Boston MC MBCCOP	33	—	—	—
Boston Medical Ctr	66	—	—	—
CRC West MI NCORP	—	—	2	—
Carle CC NCORP	—	10	—	—
Columbia MUNCORP	263	9	5	—
Columbus NCORP	—	3	2	—
Cookeville Reg MC	—	—	—	2
Dayton NCORP	—	—	2	—
Desert Hospital	73	—	—	—
Georgia NCORP	—	—	1	—
Greenville NCORP	524	14	4	—
Gulf South MUNCORP	404	1	—	—
Harrington CC	140	—	—	—
Hawaii MUNCORP	82	—	—	—
Heartland NCORP	—	25	1	—
Kaiser Perm NCORP	608	—	—	—
Loyola University	68	—	—	—
MD Anderson CC	351	—	—	—
Michigan CRC NCORP	—	—	1	—
Montana NCORP	32	—	—	—
Ozarks NCORP	—	31	—	—
PCRC NCORP	6	4	—	—
Providence Hosp	—	—	—	2
San Antonio, U of TX	145	—	—	—
Southeast COR NCORP	—	6	—	—
Sutter Cancer RC	10	—	—	—
VAMC Kansas City	96	—	—	—
Wayne State Univ	—	—	—	1
Wichita NCORP	—	9	1	—
<b>Total</b>	<b>2,989</b>	<b>112</b>	<b>19</b>	<b>5</b>

## Hope Foundation Heads-Up

**July 1 deadline:** SWOG Early Exploration and Development (SEED) Fund

**August 1 deadline:** SWOG/Hope Impact Award Program

**September 1 deadline:** SWOG VA Integration Support Program

THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*

LEARN MORE AT [THEHOPEFOUNDATION.ORG](http://THEHOPEFOUNDATION.ORG)

# Cancer Survivorship Committee

## Leadership

Co-Chairs: ..... Carol J. Fabian, M.D.  
 ..... Robert S. Krouse, M.D.

## Time/Location

Thursday, April 27, 2017 8:00 a.m. - 10:00 a.m.  
 Room: Bayview B (Bay Level)

## Plenary

Lifestyle Interventions to Promote Improved Survival and Quality of Life:  
 The Role of Cooperative Group Trials. Cyndi Thomson, Ph.D.

## Approved Studies

**S1501**, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer." Drs. Floyd and Leja.

## Update of Concepts Previously Proposed

A fractional factorial trial to identify the most effective method to increase physical activity among colorectal cancer survivors. Dr. Greenlee.

Weight Loss in Newly Diagnosed Prostate Cancer. Dr. Hamilton-Reeves.

A phase II trial of flibanserin to improve desire in women with cancer. Dr. Dizon.

## New Concepts

Testosterone replacement and exercise in hypogonadal prostate cancer survivors. Dr. Dorff.

Text Intervention to Improve Cardiovascular Health In Breast Cancer Survivors. Dr. Hershman.

## Update on Pilots for New Concepts

Docosahexaenoic Acid (DHA) versus Placebo during Adjuvant Therapy for Prevention of Cognitive Dysfunction Pilot feasibility study (Secondary Committee Breast). Dr. Fabian.

A Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors. Dr. Sun.

## Active Studies

**S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15.

## Cancer Survivorship Committee

### Cumulative Accrual by Institution and Study

For the Period Ending  
 January 31, 2017  
 Currently Open Studies or  
 Studies Closed after July 1, 2015

	S1316
Arizona MC, U of	7
Arkansas, U of	5
City of Hope Med Ctr	4
Columbia MU-NCORP	1
Kansas, U of	3
MD Anderson CC	1
MUSC MU-NCORP	5
Michigan, U of	6
Tennessee, U of	6
Alliance	5
NRG	18
<b>Total</b>	<b>61</b>

## Subcommittee Updates

Sarcoma Survivorship: Lara Davis, M.D. and Laurence H. Baker, D.O.

GU Survivorship: Peter Van Veldhuizen, M.D.

Palliative Medicine: Frank L. Meyskens, M.D.

Cancer Survivorship Website Project: Mark O'Rourke, M.D., Jennifer Klemp, Ph.D., and Marian Neuhouser, Ph.D., R.D.

Oncology Research Professionals Update: Jamie Myers APRN, Ph.D.

Advocate Update: Rick Bangs and Anna Gottlieb.

## Other Business

# Prevention & Epidemiology Committee

## Leadership

Co-Chair: ..... Marian Neuhouser, Ph.D., R.D.  
..... Banu Arun, M.D.

## Time/Location

Thursday, April 27, 2017 12:30 p.m. - 2:30 p.m.

Room: Bayview B (Bay Level)

## Presentations:

Welcome and Opening Comments - Dr. Marian Neuhouser and Dr. Banu Arun

The Cancer Moonshot and Prevention - Dr. Ernie Hawk, UT MD Anderson Cancer Center

## Active Studies

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III." Drs. Zell, Brown, Lance, Krouse and Lipkin. Activated: 3/1/13.

NHLBI-MDS, The National Myelodysplastic Syndromes Natural History Study. Dr. Hill.

## Closed Studies

**S0812**, "A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer, Phase IIB." Dr. Crew. Activated: 11/1/11; Closed: 8/15/14.

## New Business

### Concepts approved by Triage

**S1711**, "Decision Support to Increase Chemoprevention Uptake Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ." Dr. Crew.

### Concepts in Development

Pilot Evaluation of Pembrolizumab in a Short-term Breast Cancer Prevention Study. Dr. Arun.

### Other Concepts to discuss

Open discussion





# Prevention & Epidemiology Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0820	A211102	A211201
Baptist MU-NCORP	1	—	—
Brooke Army Med Ctr	2	—	—
CORA NCORP	2	—	—
City of Hope Med Ctr	1	1	—
Colorado, U of	2	—	—
Columbia MU-NCORP	1	1	2
Columbus NCORP	2	—	—
Essentia Hlth NCORP	3	—	—
Georgia NCORP	2	—	—
Hawaii MU-NCORP	4	—	—
Heartland NCORP	2	—	—
Irvine, U of CA	12	—	—
Kaiser Perm NCORP	16	—	9
Kansas, U of	3	—	—
Lahey Hosp & Med Ctr	—	—	1
Loma Linda Univ	1	—	—
Loyola University	1	—	—
MAVERIC	2	—	—
MD Anderson CC	8	—	—
Michigan CRC NCORP	2	—	—
Michigan, U of	—	—	2
Mississippi, Univ of	1	—	—
Northwest NCORP	3	—	—
Oklahoma, Univ of	1	—	—
Providence Hosp	1	—	—
San Antonio, U of TX	5	—	—
So Calif, U of	3	—	—
Southeast COR NCORP	1	—	—
Wayne State Univ	2	—	—
Wichita NCORP	6	—	—
Yale University	4	—	—
Alliance	12	—	—
ECOG-ACRIN	9	—	—
NRG	9	—	—
<b>Total</b>	<b>124</b>	<b>2</b>	<b>14</b>

Save the date  
for the fall  
meeting

October 11-14 2017 | Chicago, IL

# Symptom Control & Quality of Life Committee

## Leadership

Co-Chairs: ..... Michael J. Fisch, M.D., M.P.H.  
 ..... Norah Lynn Henry, M.D., Ph.D.

## Time/Location

Thursday, April 27, 2017 10:15 a.m. - 12:15 p.m.  
 Room: Bayview B (Bay Level)

## Feature Presentations (70 minutes)

Lynn Henry, M.D. Ph.D.: S1202, "A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer."

Amy Darke, M.S.: Understanding the available SWOG data related to PROs and biospecimens.

Sarah Mougalian, M.D.: "Breast Cancer Endocrine Toxicity and Adherence Text Messaging Feasibility (BETA) Study."

## Trials under development (30 minutes)

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Dr. Hamilton-Reeves.

**S1614**, "Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors." Dr. Hwang.

"A prospective observational cohort study to develop a predictive model of taxane-induced peripheral neuropathy in cancer patients." Dr. Trivedi.

## Discussion topics related to PROs (20 minutes to end of meeting)

Approach to using the PROCTCAE

Update on BQSF

ePRO

## Closed Studies

**S1013**, "A Phase II Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy – EGFR 18 (FACT-EGFR 18) Questionnaire for EGFR-induced Skin Toxicities." Drs. Wong, Moinpour, and Wade. Activated: 11/15/11. Closed: 10/1/16.

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in

Women with Early Stage Breast Cancer." Drs. Hershman and Crew. Activated: 4/1/12. Closed: 2/15/17.

## Other Concepts in Development

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Dr. Hamilton-Reeves.

**S1614**, "Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors." Dr. Hwang.

**S1710**, "A Randomized Phase II Multicenter Non-Inferiority Trial of Rivaroxaban 10 mg daily versus Low Molecular Weight Heparin for Prevention of Thromboembolism in Patients Being Treated with an Immunomodulatory-Based Regimen for Multiple Myeloma." Drs. Calverley and Myers.

"Cognitive Rehabilitation Intervention during Cancer Treatment: Emerging from the Haze." Drs. Asher and Myers.

"A Phase II Randomized Placebo-Controlled Study to Evaluate the Use of vitamin K1 Topical Lotion in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor (HER1/EGFR) Inhibitors." Drs. Wong, Moinpour, and Wade.

"A prospective observational cohort study to develop a predictive model of taxane-induced peripheral neuropathy in cancer patients." Dr. Trivedi.

"Breast Cancer Endocrine Toxicity and Adherence Text Messaging Feasibility Study." Dr. Mougalian.

## Other Active Studies with Symptom Control and QOL Component

**S1207**, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer." Drs. Chavez-MacGregor and Puztai Activated: 9/1/13.

**S1404**, "A Phase III Randomized Study of MK-3475 (Pembrolizumab) versus High-Dose Interferon alpha-2b for Resected High-Risk Melanoma." Drs. Grossmann and Patel. Activated: 10/15/15.

**CTSU/A011401**, "Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer." Dr. Hershman. Activated: 2/21/14.

# Symptom Control & Quality of Life Committee

**CTSU/A021202**, "Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors." Dr. Phan. Activated: 1/15/14. Closed: 10/7/16.

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. Quinn. Activated: 7/1/15.

**CTSU/C51101**, "A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma." Dr. Mohile. Activated: 7/1/12.

**CTSU/E1411**, "Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)." Dr. Till. Activated: 5/22/12. Closed: 9/9/16.

**CTSU/E1912**, "A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. O'Brien. Activated: 2/15/14. Closed: 6/9/16.

**CTSU/E1A11**, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Dr. Zonder. Activated: 2/1/14.

**CTSU/E1Z11**, "A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)." Dr. Henry. Activated: 5/21/13.

**CTSU/E2112**, "A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer." Dr. Royce. Activated: 3/29/14.

**CTSU/E2810**, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastectomy." Dr. Pal. Activated: 9/1/12.

**CTSU/E3A06**, "Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma." Dr. Dhodapkar. Activated: 2/1/11.

**CTSU/EA6134**, "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma." Dr. Chmielowski. Activated: 7/13/15.

**CTSU/N1048**, "A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Dr. Eng. Activated: 4/15/12.

**CTSU/NRGCC003**, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activated: 12/7/15.

**CTSU/NSABP-B-55**, "A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy." Dr. Sharma. Activated: 7/3/14.

**CTSU/R0848**, "A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma." Dr. Philip. Activated: 12/15/09.

## Committee Process

Please sign in and/or correct the meeting attendance/contact list



# Symptom Control & Quality of Life Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1013	S1200	S1202	A221101	A221102	NRGCC002	SCUSF806
Arkansas, U of	—	—	10	1	—	1	—
Baptist MU-NCORP	—	—	2	—	—	—	—
Beaumont NCORP	—	—	2	—	—	—	—
Brooke Army Med Ctr	—	—	1	—	—	—	—
CORA NCORP	—	—	—	—	7	—	1
CRC West MI NCORP	—	65	—	—	—	—	—
Cedars-Sinai Med Ctr	—	—	3	—	—	—	—
City of Hope Med Ctr	20	—	—	—	—	—	—
Columbia MU-NCORP	3	29	1	—	—	—	—
Columbus NCORP	—	—	1	—	—	—	—
Davis, U of CA	—	—	—	—	—	—	1
Dayton NCORP	—	—	6	—	—	—	—
Franciscan Res Ctr	—	—	1	—	—	—	—
Fred Hutchinson CRC	—	11	—	—	—	—	—
Georgia NCORP	—	—	—	—	—	—	1
Greenville NCORP	—	15	1	—	—	—	—
Gulf South MU-NCORP	12	—	18	—	—	—	—
H Lee Moffitt CC	—	—	1	—	—	—	—
Hawaii MU-NCORP	—	—	3	—	—	—	—
Heartland NCORP	61	—	11	—	—	—	3
Irvine, U of CA	—	—	3	7	—	—	—
Kaiser Perm NCORP	—	56	40	—	—	—	—
Kansas City NCORP	1	—	2	—	—	—	—
Kentucky, U of	—	-	—	1	—	—	—
Lahey Hosp & Med Ctr	-	10	—	—	—	—	—
Loma Linda Univ	1	—	—	—	—	—	—
Loyola University	—	—	3	—	—	—	—
MUSC MU-NCORP	—	—	2	—	—	—	—
Michigan CRC NCORP	—	—	9	—	—	—	—
Michigan, U of	—	—	2	—	—	—	—
Montana NCORP	—	—	5	—	—	—	—
Nevada CRF NCORP	—	—	1	—	—	—	—
New Mexico MU-NCORP	—	—	1	—	—	—	2
Northwest NCORP	—	—	6	1	—	—	—
Oregon Hlth Sci Univ	—	9	—	—	—	—	2
Ozarks NCORP	—	—	1	—	—	—	—
PCRC NCORP	—	19	6	—	—	—	—
Providence Hosp	—	—	—	2	—	—	2
San Antonio, U of TX	—	—	4	—	—	—	—
So Calif, U of	26	5	—	—	—	—	—
Southeast COR NCORP	5	—	17	—	—	—	—
Sutter Cancer RC	—	—	3	1	2	—	—
Tulane Univ MBCCOP	—	—	1	—	—	—	—
Tulane University	—	—	5	—	—	—	—
Upstate Carolina	—	—	—	1	—	—	—
Utah, U of	—	3	—	—	—	—	—
Wayne State Univ	3	—	4	—	—	—	7
Wichita NCORP	14	—	13	—	—	—	—
Alliance	—	—	43	—	—	—	—
ECOG-ACRIN	—	—	23	—	—	—	—
NRG	—	—	44	—	—	—	—
<b>Total</b>	<b>146</b>	<b>222</b>	<b>299</b>	<b>14</b>	<b>9</b>	<b>1</b>	<b>19</b>

# Early Therapeutics & Rare Cancers Committee

## Leadership

Chair: ..... Razelle Kurzrock, M.D.  
 Executive Officer: ..... Christopher W. Ryan, M.D.  
 Statisticians: ..... Megan Othus, Ph.D.  
 ..... Melissa Plets, M.S.  
 ..... Cyrus Ebnesajjad, M.S.

## Designates

Data Coordinators: ..... Laura Kingsbury, M.R.T.  
 ..... Christine McLeod  
 Oncology Research Professionals:  
 CRA: ..... Corrine Turrell, C.C.R.P.  
 Nurse: ..... TBD  
 Pharmaceutical Science: ..... Siu-Fun Wong, Pharm.D.  
 Patient Advocate: ..... Marcia K. Horn, J.D.  
 Protocol Coordinator: ..... Cara Laubach

## Early Therapeutics Liaisons

Breast Committee Liaison: ..... George Somlo, M.D.  
 Genitourinary Committee Liaison: ..... Neeraj Agarwal, M.D.  
 Imaging: ..... Oliver Press, M.D.  
 Lung Committee Liaison: ..... Shirish M. Gadgil, M.D.  
 Lymphoma Committee Liaison: ..... Daruka Mahadevan, M.D., Ph.D.  
 Melanoma Committee Liaison: ..... Jeffrey A. Sosman, M.D.  
 Myeloma Committee Liaison: ..... Frits van Rhee, M.D., Ph.D.

## Time/Location

Thursday, April 27, 2017 10:00 a.m. - 12:15 p.m.  
 Room: Seaclyff A-C (Bay Level)

## Introduction

**10:00 - 10:05 am:** Razelle Kurzrock, MD, Senior Deputy Center Director, UCSD Moores Cancer Center

## Presentations

**10:05 – 10:25 am:** “S1618: A Phase II Study of a selective JAK1 Inhibitor (INC39110) in Subjects with Advanced Sarcomas,” Victor M. Villalobos, MD, PhD, Assistant Professor of Medicine, Director, Sarcoma Medical Oncology, Director, Target-based Therapeutics Team (T3), University of Colorado Denver, Anschutz Medical Campus.

**10:25 – 10:55 am:** “New Developments in Early Therapeutics: What Is New?,” Monica Mita, MD, Associate Professor, Department of Medicine; Co-Director, Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

**10:55 – 11:25 am:** “DART: Update on Immunotherapy for Rare Tumor Trial Initiation,” Sandip Patel, MD, Assistant Professor, UCSD Moores Cancer Center and Young K. Chae, MD, MPH, Assistant Professor, Northwestern University.

**11:25 – 11:45 am:** “S1708: A Randomized Trial of Anetumab Ravtansine versus Investigator Choice (Vinorelbine or Gemcitabine) in Previously Treated Patients with Advanced Malignant Peritoneal Mesothelioma,” Kanwal Raghav, MD, MBBS, Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

**11:45 am-12:05 pm:** “Phase 2 Study of Tazemetostat in ARID1A Deficient Cancer,” Siqing Fu, MD, PhD, Associate Professor, Department of Investigational Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

## Active Studies

**S1609,** “DART Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. Patel, Chae, Giles, and Kurzrock.

**CTSU/A071102,** “A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Te-mozolomide in Newly Diagnosed MGMT Promoter Hypermethylation.” Dr. Piccioni. Activated by Alliance: 12/15/14. Activated by SWOG: 4/1/15.

**CTSU/A071401,** “Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/ NF2 Mutations.” Dr. Piccioni. Activated by Alliance: 8/28/15. Activated by SWOG: 1/1/16.

**CTSU/ARST1321,** “Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613).” Dr. Villalobos. Activated by COG: 1/27/14. Activated by SWOG: 3/15/16.

**CTSU/EAY131,** “Molecular Analysis for Therapy Choice (MATCH).” Dr. Villalobos. Activated by Alliance and SWOG: 8/12/15.

## Closed Studies

**CTSU/NRG-CC002,** “NCT # 02315469: Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers. Dr. Robinson. Activated by SWOG: 10/1/15. Closed: 11/2/15.

# Early Therapeutics & Rare Cancers Committee

## Proposed Studies

**S1708**, "Randomized Phase II Study of Anti-Mesothelin ADC in Malignant Peritoneal Mesothelioma." Dr. Raghav.

**SXXXX**, "A Phase II Study of a selective JAK1 Inhibitor (INCB9110) in Subjects with Advanced Sarcomas." Dr. Villalobos.

**SXXXX**, "A Phase I/II study of Brentuximab Vedotin in CD30 + Systemic Mastocytosis and CMML." Drs. Borate and Gerdts.

**SXXXX**, "Randomized Phase III trial of the CancerTYPE ID test in the evaluation of patients with cancer of unknown primary (CUP)." Drs. Yentz and Baker.

**SXXXX**, "A Phase II Study of Tazemetostat in Advanced Gynecologic Malignancies." Dr. Fu.

**SXXXX**, "Efficacy and Safety of Laparoscopic Extraperitoneal Para-aortic Lymphadenectomy vs. PET/CT as a Classificatory Method for the Treatment of Locally Advanced Cervical Cancer, a Phase III Randomized Clinical Trial." Dr. Acosta.

**CTSU/GOG-0286B**, "A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (NCT #0265687)." Dr. Verschraegen.



**WEDNESDAY,  
OCTOBER 11  
Fall 2017 SWOG  
Group Meeting  
Chicago**

**New agenda and  
topics at each  
Workshop!**

3<sup>RD</sup> Annual

## SWOG NCORP Research Base Clinical Trials Workshop

For Clinical Research Professionals and Investigators at NCORP, Member and LAPS Institutions and Affiliates


A HOPE FOUNDATION sponsored Clinical Trials Training Course

NCORP studies in the following SWOG research areas will be discussed:

**Cancer Survivorship | Prevention & Epidemiology | Cancer Care Delivery Research | Symptom Control and Quality of Life**

The workshop consists of didactic presentations and breakout sessions for information sharing.

Contact [cancercontrolquestion@crab.org](mailto:cancercontrolquestion@crab.org) with topic suggestions or questions.

**SWOG**  Leading cancer research. Together.

THE HOPE FOUNDATION  
*Because answers to cancers come from clinical trials*

**NCI** Community Oncology  
Research Program  
A program of the National Cancer Institute  
of the National Institutes of Health





# Early Therapeutics & Rare Cancers Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1609	A071102	A071401	ARST1321	EAY131
Arkansas, U of	—	—	—	—	2
Baylor College	—	2	—	—	—
Brooke Army Med Ctr	—	2	—	—	—
CORA NCORP	—	1	1	—	1
Cedars-Sinai Med Ctr	—	—	—	—	2
Cleveland Clinic OH	—	—	—	—	4
Colorado, U of	—	2	1	—	6
Davis, U of CA	—	—	—	—	2
Dayton NCORP	—	—	—	—	1
Hawaii MU-NCORP	—	—	—	—	1
Henry Ford Hosp	—	—	—	—	6
Irvine, U of CA	—	1	1	—	—
Kaiser Perm NCORP	—	3	—	—	3
Kansas City NCORP	—	—	—	—	1
Kansas, U of	—	—	—	1	1
Kentucky, U of	—	—	—	—	5
Lahey Hosp & Med Ctr	—	3	—	—	—
Methodist Hospital	—	—	—	—	1
Michigan, U of	—	—	—	—	4
Mississippi, Univ of	—	1	—	—	—
Montana NCORP	1	—	—	—	—
Northwestern Univ	—	1	—	1	—
Ozarks NCORP	—	2	—	—	—
PCRC NCORP	—	3	—	—	—
Providence Hosp	—	—	—	—	1
Rochester, Univ of	—	8	—	—	—
San Antonio, U of TX	—	—	—	—	1
San Diego, U of CA	—	7	2	—	—
Southeast COR NCORP	—	—	—	—	4
Sutter Cancer RC	—	—	—	—	2
Tulane University	—	—	—	—	1
Yale University	—	1	—	—	4
<b>Total</b>	<b>1</b>	<b>37</b>	<b>5</b>	<b>2</b>	<b>53</b>



# Gastrointestinal Committee

## Leadership

Chair: .....Howard S. Hochster, M.D.  
 Vice-Chair: .....Heinz-Josef Lenz, M.D.  
 Executive Officer: .....Christopher W. Ryan, M.D.  
 Statisticians: .....Katherine Guthrie, Ph.D.  
 .....Shannon McDonough, M.S.

## Scientific Leadership

Gastroesophageal: .....Syma Iqbal, M.D.  
 .....Lawrence P. Leichman, M.D.  
 .....Scott A. Hundahl, M.D. (Surgical representative)  
 Pancreatic: .....Philip A. Philip, M.D., Ph.D.  
 .....Andrew M. Lowy, M.D. (Surgical representative)  
 Hepatobiliary: .....Anthony B. El-Khoueiry, M.D.  
 .....Milind Javie, M.D.  
 .....Syed Ahmad, M.D. (Surgical representative)  
 Colon: .....Philip J. Gold, M.D.  
 .....Wells A. Messersmith, M.D.  
 .....Kevin G. Billingsley, M.D. (Surgical representative)  
 Rectal: .....Lisa A. Kachnic, M.D.  
 .....Cathy Eng, M.D.  
 Translational Medicine: .....Heinz-Josef Lenz, M.D.  
 .....Christopher H. Lieu, M.D.  
 Drug Development: .....Ramesh Ramanathan, M.D.  
 .....Sunil Sharma, M.D.  
 Imaging: .....Anthony F. Shields, M.D., Ph.D.  
 .....David Shin-Kuo Lu, M.D.  
 Radiation Oncology: .....Lisa A. Kachnic, M.D.

## Designates

Cancer Control Liaison: .....Jason A. Zell, D.O.  
 Data Coordinators: .....Christine McLeod  
 .....Jacqueline Scurlock  
 .....Brian Zeller  
 Oncology Research Professionals:  
 CRA: .....Sandy Annis, C.C.R.P.  
 Nurses: .....Rita Kaul, R.N., B.S.N.  
 .....Valerie A. Parks, R.N.  
 Patient Advocate (Pancreatic): .....Carole Seigel  
 Patient Advocate (Colon): .....Florence Kurttila  
 Pharmaceutical Science: .....Linda Lee-Gabel, Pharm.D.  
 .....Manj Randhawa, Pharm.D.  
 Protocol Coordinator: .....Danae Campos

## Time/Location

Friday, April 28, 2017 5:00 p.m. - 7:00 p.m.  
 Room: Grand C (Street Level)

Introduction - Howard Hochster, M.D., Yale University.

"Treatment resistance to anti-EGFR therapy and ctDNA". Scott Kopetz, M.D., Ph.D., MD Anderson Cancer Center.

Presentation of S1417, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Veena Shankaran, M.D., Fred Hutchinson Cancer Research Center.

## Gastroesophageal

### Active Studies

**CTSU/A021302**, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study." Dr. Iqbal. Activated: 4/1/16

### Closed Studies

**S1201**, "A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer." Dr. Iqbal. Activated: 3/1/12

## Pancreatic

### Active Studies

**S1313**, "A Phase II Randomized Study of FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus FOLFIRINOX Alone in Patients with Metastatic Pancreatic Adenocarcinoma." Dr. Ramanathan. Activated: 1/15/14.

**S1505**, "A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma." Dr. Sohal. Activated: 10/12/15.

**S1513**, "Randomized Phase II Study of 2nd Line Therapy with FOLFIRI with or without PARP Inhibitor Veliparib (ABT-888) in Metastatic Pancreatic Cancer." Dr. Chiorean. Activated: 9/1/16.

**CTSU/RTOG 0848**, "A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma." Dr. Philip. Activated: 12/15/09.

### Proposed Studies

"A Phase II Study of CCR2 Inhibition testing Folfirinox in Combination with PF-04136309 vs Folfirinox Alone in Locally Advanced Pancreatic Cancer." Dr. Noel.

# Gastrointestinal Committee

**CTSU/A021501**, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." Dr. Ahmad.

## Closed

**CTSU/E2211**, "A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors." Dr. Wolin. Activated: 3/1/12.

**CTSU/RT0G-1201**, "A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer." Dr. Murphy. Activated: 3/1/15.

## Hepatobiliary

## Closed

**S1310**, "Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer." Dr. Kim. Activated: 2/15/14

## Colon

## Active Studies

**S0820**, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III." Dr. Zell. Activated: 3/1/13.

**S1417CD**, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. Shankaran. Activated: 5/13/16

**S1415CD**, "Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia – Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)." Drs. Ramsey and Hershman. Activated: 9/1/16.

**CTSU/E7208**, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." Dr. Hochster. Activated: 7/1/14.

## Closed

**S1406**, "Randomized Phase II Study of Irinotecan and Cetuximab with or

without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer." Dr. Kopetz. Activated: 11/14/15.

## Proposed Studies

**S1613**, "A Randomized Phase 2 study of Trastuzumab and Pertuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-refractory Metastatic Colorectal Cancer (mCRC)." Dr. Raghav.

## Rectal

## Active Studies

**CTSU/N1048**, "A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Dr. Eng. Activated: 4/15/12.

**CTSU/EA2133**, "InterAACT – An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." Dr. Morris. Activated: 2/15/16.

## Other

## Active Studies

**S1013**, "A Phase II Prospective Study of Epidermal Growth Factor Receptor (Her01/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy – EGFR 18 (FACT-EGFR 18) Questionnaire for EGFR-Induced Skin Toxicities." Drs. Wong, Moinpour, and Wade. Activated: 11/15/11.

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13.

**CTSU/A021202**, "Prospective Randomized Phase II Trial of Pazopanib versus Placebo in Patients with Progressive Carcinoid Tumors." Dr. Phan. Activated: 1/15/14.

**S1316**, "Prospective Comparative Effectiveness Trial For Malignant Bowel Obstruction." Dr. Krouse. Activated: 3/9/15.

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Dr. Patel. Activated: 1/13/17.



# Gastrointestinal Committee

**EAY131**, "NCI-MATCH: Molecular Analysis for Therapy Choice." Dr. Flaherty.  
Activated: 8/12/15.

## Correlative Studies

**S9008A**, "Trial of Adjuvant Chemoradiation after Gastric Resection  
Adenocarcinoma, Phase III." Dr. Shridhar.

**S-C80405-A**, "Analysis of EGFR and ERCC1 Markers and Progression-  
Free Survival in Patients with Advanced Colorectal Cancer Enrolled on  
C80405." Drs. Shields and Lenz.

## Other Proposed Studies


"A Randomized Phase II/III Study of Gemcitabine and Cisplatin followed by  
Capecitabine/Radiation versus Gemcitabine and Cisplatin Alone." Dr.  
El-Khoueiry.



## SWOG Offices

1. SWOG Statistics and Data Management Center,  
Fred Hutchinson Cancer Research Center, Seattle, WA
2. SWOG Group Chair's Office, Knight Cancer Institute  
at Oregon Health & Science University, Portland, OR
3. The Hope Foundation, Ann Arbor, MI
4. SWOG Operations, San Antonio, TX

Dr. Grant Taylor,  
first SWOG  
group chair



## Our History

Founded in 1956 by the National Cancer Institute, we are part of the NCI's National Clinical Trials Network, the largest and oldest publicly funded cancer research network in the United States. We are also part of NCI's Community Oncology Research Program, which connects us to community hospitals and clinics across the nation – and the diverse populations they serve.



Our members include 12,000 research professionals working in 47 states and six other countries, and our biorepository holds more than 700,000 specimens accessible to fellow researchers around the world.

## Gastrointestinal Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1313	S1406	S1505	S1513	A021202	C80702	E2211	E7208	EA2142	N1048	R0848	R1010	R1201
Arizona MC, U of	4	—	—	—	—	—	—	—	—	4	—	—	—
Baptist MU-NCORP	—	1	—	—	—	2	—	—	—	—	—	—	—
Baylor College	—	—	—	—	—	10	—	—	—	14	—	—	—
Baylor Univ Med Ctr	—	—	—	—	2	—	—	—	—	—	—	—	—
Boston MC MBCCOP	—	—	—	—	—	5	—	—	—	—	—	—	—
Boston Medical Ctr	—	—	—	—	—	1	1	—	—	2	—	—	—
Brooke Army Med Ctr	—	—	—	—	—	2	—	—	—	—	—	—	—
CORA NCORP	—	1	—	1	—	2	—	1	—	2	—	—	1
Carle CC NCORP	—	—	2	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	—	—	—	—	4	—	13	—	—	—	—	—	—
Cincinnati MC, U of	—	—	2	—	—	4	3	—	—	—	—	—	—
City of Hope Med Ctr	3	3	—	—	—	2	—	—	—	—	—	—	—
Cleveland Clinic OH	—	4	2	—	—	27	2	—	—	—	—	—	—
Colorado, U of	—	4	—	—	1	7	—	—	—	—	—	—	—
Columbia MU-NCORP	—	—	—	—	—	4	—	—	—	—	2	—	—
Columbia University	—	—	—	—	—	—	—	—	—	—	1	—	—
Columbus NCORP	—	2	—	—	—	7	—	—	—	—	—	—	—
Davis, U of CA	1	—	—	—	—	21	—	—	—	2	—	—	—
Dayton NCORP	—	—	1	1	—	2	—	—	—	1	—	—	—
Desert Hospital	—	—	—	—	—	5	—	—	—	—	—	—	—
Essentia Hlth NCORP	—	1	—	—	—	—	—	—	—	—	—	—	—
Franciscan Res Ctr	—	—	—	—	—	1	—	—	—	—	—	—	—
Fred Hutchinson CRC	14	—	—	—	—	2	—	—	—	9	—	—	—
Greenville NCORP	—	1	2	—	—	2	2	—	—	—	1	—	—
Gulf South MU-NCORP	—	2	—	—	—	13	—	—	—	—	—	—	—
H Lee Moffitt CC	—	—	—	—	22	1	10	—	—	—	—	—	—
Harrison Medical Ctr	—	—	—	—	—	3	—	—	—	—	—	—	—
Hawaii MU-NCORP	—	—	—	—	—	13	—	—	—	—	1	—	—
Heartland NCORP	8	2	5	—	—	26	—	—	—	—	—	2	—
Irvine, U of CA	7	1	—	—	—	9	—	—	—	7	6	1	—
Kaiser Perm NCORP	—	8	4	—	1	102	5	—	—	19	—	—	—
Kansas City NCORP	6	—	—	—	—	1	1	—	—	—	—	—	—
Kansas, U of	—	3	—	—	1	42	5	—	—	—	1	—	—
Kentucky, U of	—	—	2	—	—	1	2	—	—	—	—	—	—
Lahey Hosp & Med Ctr	—	—	—	—	—	2	1	—	—	10	—	—	—

Lives improved.  
Lives lengthened.  
Lives saved.



Leading cancer research. Together.

## Gastrointestinal Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1313	S1406	S1505	S1513	A021202	C80702	E2211	E7208	EA2142	N1048	R0848	R1010	R1201
Loyola University	—	—	—	—	—	8	1	—	—	—	4	—	—
MD Anderson CC	—	18	—	—	—	14	—	—	—	—	—	—	—
MUSC MU-NCORP	4	—	3	—	—	3	—	—	—	—	—	—	—
Madigan Army Med Ctr	—	—	—	—	—	2	—	—	—	—	—	—	—
Methodist Hospital	—	—	—	—	1	—	—	—	—	8	—	—	—
Michigan CRC NCORP	—	—	—	—	—	9	—	—	—	—	—	—	—
Michigan, U of	—	2	5	—	—	5	1	1	1	3	—	—	—
Mississippi, Univ of	—	—	—	—	—	3	—	—	—	—	—	—	—
Montana NCORP	—	—	—	—	—	2	—	—	—	—	—	—	—
New Mexico MU-NCORP	—	—	—	—	—	1	—	—	—	—	—	—	—
Northwest NCORP	—	1	—	—	—	5	—	—	—	—	3	—	—
Northwestern Univ	—	—	—	—	—	1	—	1	—	1	—	—	—
Oregon Hlth Sci Univ	—	—	1	—	—	15	—	—	—	—	—	2	—
Ozarks NCORP	—	1	—	—	—	12	—	—	—	1	—	—	—
PCRC NCORP	6	1	4	—	—	22	—	—	—	1	—	—	—
Providence Hosp	—	1	—	—	—	10	—	1	—	—	—	—	—
Rochester, Univ of	—	—	3	3	1	15	4	—	—	16	—	—	—
San Antonio, U of TX	—	1	—	—	2	14	—	—	—	—	—	—	—
San Diego, U of CA	—	—	3	—	—	—	—	—	—	4	—	—	—
Scott & White CCOP	—	—	—	—	—	3	—	—	—	—	—	—	—
Scott & White Mem	—	—	—	—	—	2	—	1	—	1	—	—	—
So Calif, U of	6	1	—	—	—	33	2	6	—	—	—	—	—
Southeast COR NCORP	5	3	2	1	—	—	—	—	—	—	—	—	—
St Louis University	—	—	—	—	—	5	—	—	—	—	—	—	—
Sutter Cancer RC	8	1	—	—	—	2	—	—	—	—	—	—	—
Tennessee, U of	—	—	—	—	—	6	—	—	—	—	—	—	—
Upstate Carolina	—	—	—	—	—	6	—	—	—	—	—	—	—
Utah, U of	—	—	—	1	—	1	—	—	—	2	—	—	—
Wayne State Univ	11	2	—	—	—	15	—	1	—	—	—	—	—
Wichita NCORP	—	—	—	—	—	5	—	—	—	—	1	—	—
Wisconsin NCORP	—	—	3	—	—	—	—	—	—	—	—	—	—
Yale University	37	5	—	—	—	2	2	6	—	—	—	—	—
Alliance	—	19	8	1	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	—	10	14	—	—	—	—	—	—	—	—	—	—
NRG	—	7	13	—	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>120</b>	<b>106</b>	<b>79</b>	<b>8</b>	<b>35</b>	<b>540</b>	<b>55</b>	<b>18</b>	<b>1</b>	<b>107</b>	<b>20</b>	<b>5</b>	<b>1</b>

# Save the date for next spring

## April 11-14, 2018 | San Francisco, CA



# Genitourinary Committee

## Leadership

Chair: ..... Ian M. Thompson, Jr., M.D.  
 Vice-Chair: ..... Nicholas J. Vogelzang, M.D.  
 Executive Officer: ..... Christopher W. Ryan, M.D.  
 Statisticians: ..... Cathy M. Tangen, Dr.P.H.  
 ..... Melissa Plets, M.S.

## Scientific Leadership

Translational Medicine: ..... David J. McConkey, Ph.D.  
 Translational Medicine Chair- Bladder ..... Joshua Meeks, M.D.  
 Translational Medicine Chair- Prostate ..... Amir Goldkorn, M.D.  
 Translational Medicine Chair- Renal ..... Brian Shuch, M.D.  
 Radiation Oncology: ..... David Raben, M.D.  
 Surgery: ..... Daniel J. Culpin, M.D.  
 Imaging: ..... Daniel W. Lin, M.D.  
 ..... John D. Hazle, Ph.D.  
 Medical Oncology: ..... Celestia S. Higano, M.D.  
 Pathology: ..... M. Scott Lucia, M.D.  
 Liaison to the SPORES: ..... Colin P.N. Dinney, M.D.  
 Early Therapeutics: ..... Neeraj Agarwal, M.D.

## Designates

Cancer Control: ..... Peter J. Van Veldhuizen, Jr., M.D.  
 Data Coordinators: ..... Diana Heaney  
 ..... Sean O'Bryan  
 ..... Joseph Sanchez  
 Oncology Research Professionals:  
 CRA: ..... Debra W. Christie, M.B.A.  
 Nurse: ..... Deborah A. Shaw, R.N.  
 Patient Advocates: ..... Rick Bangs (Bladder)  
 ..... Tony Crispino (Prostate)  
 Pharmaceutical Science: ..... Joyce Lee, Pharm.D.  
 ..... Rivka Siden, Pharm.D.  
 Protocol Coordinator: ..... Nicki Trevino

## Time/Location

Saturday, April 29, 2017 9:30 a.m. - 12:30 p.m.  
 Room: Grand A (Street Level)

**Introductions and Announcements** - Ian M. Thompson, Jr., M.D.

**Translational Medicine in the GU Committee** - David J. McConkey, Ph.D. and Christopher W. Ryan, M.D.

## Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

## Active Studies

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13.

**S1316**, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Krouse, Badgwell, and Sun. Activated: 3/7/15.

## Renal

Organ Site Chairs: Drs. Primo N. Lara, Jr. (Advanced) and Edward M. Messing (Local)

## Active Studies

**S1500**, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. Pal, Lara, and Shuch. Activated: 4/5/16.

**CTSU/E2810**, "Randomized Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatec-tomy." Dr. Pal. Activated: 9/1/12.

**CTSU/EA8143**, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing." Drs. Lara and Shuch. Activated: 2/2/17.

## Closed Studies

**S1107**, "Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARG 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma." Drs. Twardowski and Lara. Closed: 5/29/14.

**S0931**, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. Ryan, Heath, Lara, Palapattu, and Mack. Activated: 4/1/11. Closed: 9/15/16.

# Genitourinary Committee

## Prostate

Organ Site Chairs: Drs. David I. Quinn (Advanced) and Daniel W. Lin (Local)

### Active Studies

**S1216.** "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. Agarwal, Goldkorn, Gupta, Hussain, and Lara; T. Crispino. Activated: 3/1/13.

**CTSU/A031102.** "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. Quinn. Activated: 7/1/15.

### Closed Studies

**S9921.** "Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III." Drs. Glode, Hussain, Swanson, Wood, and Sakr.

**CTSU/A031201.** "A Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer." Dr. Amir Goldkorn. Activated: 2/1/14. Closed: 8/31/16.

## Bladder

Organ Site Chairs: Drs. Daniel P. Petrylak (Advanced) and Seth P. Lerner (Local)

### Active Studies

**S1602.** "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Dr. Svatek. Activated: 2/7/17.

**S1605.** "A Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. Black and Singh. Activated: 2/7/17.

**S1314.** "A Randomized Phase II Study of CO-eXpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer." Drs. Flaig, Alva, Daneshmand, Goldkorn, Lerner, Lucia, McConkey, and Theodorescu. Activated: 7/9/14.

**CTSU/EA8141.** A Prospective Phase II Trial of Neoadjuvant Systemic

Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. Drs. Godoy and Alva. Activated: 4/10/15.

### Closed Studies

**S0337.** "A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly-Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer." Drs. Messing, Sahasrabudhe, Koppie, Wood, and Mack.

**S1011.** "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. Lerner, Alva, Koppie, LaRosa, Pal, and Svatek; R. Bangs. Closed: 2/15/17.

### Diverse Studies of Interest

**S1609.** "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel and Chae. Activated: 1/13/17.

**CTSU/EAY 131.** "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/15.

SWOG Champions needed: R0815, R0924

## GO MOBILE AT THE MEETING

*We're excited to announce we have a brand new mobile guide for you to use on Guidebook! Get the guide to access the most up-to-date information about our event, including schedules, maps, and much more.*

**Get our guide here: <https://guidebook.com/g/swogspring2017>**

**Android and iOS users:**

1. Tap the "Download" button to download the free Guidebook app
2. Open Guidebook and you can find our "SWOG Spring 2017 Group Meeting" guide

**See you there!**

— SWOG Spring 2017  
Group Meeting Team



**COMPATIBLE WITH IPHONES, IPADS, ANDROID AND BLACKBERRY DEVICES**

# Genitourinary Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0931	S1011	S1216	S1314	S1500	A031102	A031201	C70807	C90203	E1808	E2810	EA8141	R0815	R0924
Arizona MC,	13	—	9	2	—	—	10	—	—	—	—	—	—	—
U of Arkansas, U of	10	—	6	—	—	—	4	—	—	—	—	—	—	—
Atlanta Reg CCOP	7	—	—	—	—	—	—	1	—	—	—	—	—	—
BC Cancer Agency	—	22	—	—	—	—	—	—	—	—	—	—	—	—
Baptist MU-NCORP	3	—	—	—	—	—	—	—	—	—	—	—	—	—
Bay Area NCORP	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Baylor College	21	50	12	3	—	—	3	10	—	—	—	—	—	—
Beaumont NCORP	8	—	2	—	—	—	—	5	—	—	—	—	—	—
Birmingham, U of AL	—	—	—	1	—	—	11	—	—	—	—	1	—	—
Boston MC MBCCOP	1	—	3	—	—	—	—	—	—	—	—	—	—	—
Boston Medical Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Brooke Army Med Ctr	2	—	—	—	—	—	—	—	—	—	—	—	—	—
CORA NCORP	7	—	2	—	—	—	3	—	—	—	—	—	1	1
CRC West MI NCORP	15	—	3	—	—	—	—	—	—	—	—	—	—	—
Carle CC NCORP	—	—	2	—	—	—	—	—	—	—	—	—	—	—
Cedars-Sinai Med Ctr	13	—	—	—	1	—	—	6	—	—	—	—	—	—
Cincinnati MC, U of	6	—	1	—	—	—	3	—	—	—	—	—	—	—
City of Hope Med Ctr	41	—	46	6	7	—	22	—	10	—	16	—	—	—
Cleveland Clinic OH	—	7	—	7	—	—	38	5	—	—	—	—	—	—
Colorado, U of	27	3	4	5	—	—	5	26	17	—	—	3	—	—
Columbia MU-NCORP	6	—	2	—	—	—	—	—	—	—	1	—	—	—
Columbia University	3	—	—	—	—	—	—	—	—	—	—	—	—	—
Columbus NCORP	17	—	6	—	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	13	12	33	1	—	—	10	—	45	—	—	—	—	—
Dayton NCORP	16	—	7	—	—	—	—	—	—	—	—	—	—	—
Desert Hospital	—	—	—	—	—	—	—	—	—	—	—	—	2	4
Fred Hutchinson CRC	3	—	27	—	—	—	—	—	—	—	—	—	—	—
Galveston, U of TX	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Georgia NCORP	2	—	2	—	—	—	1	—	—	—	1	—	—	—
Greenville NCORP	6	—	—	1	—	—	—	—	—	—	—	—	—	—
Gulf Coast MBCCOP	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	17	4	2	1	—	—	—	2	3	—	—	—	—	—
H Lee Moffitt CC	—	2	32	—	—	—	—	—	2	—	—	—	—	—
Harrison Medical Ctr	—	—	—	—	—	—	2	—	—	—	—	—	—	—
Hawaii MU-NCORP	13	—	—	—	—	—	1	—	—	—	—	—	—	—
Heartland NCORP	37	—	34	15	—	—	3	3	2	—	—	—	2	—
Henry Ford Hosp	8	—	—	—	—	—	14	—	1	—	1	—	—	—
Irvine, U of CA	8	—	6	—	—	—	2	—	5	—	—	—	—	—
Kaiser Perm NCORP	14	—	76	—	—	—	97	1	—	—	—	—	—	—
Kansas City NCORP	7	—	6	—	—	—	—	—	—	—	—	—	—	—
Kansas, U of	29	—	25	9	—	—	9	13	13	1	6	1	—	—
Kentucky, U of	—	—	15	—	—	—	—	4	—	—	—	—	—	—



## Genitourinary Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0931	S1011	S1216	S1314	S1500	A031102	A031201	C70807	C90203	E1808	E2810	EA8141	R0815	R0924
Lahey Hosp & Med Ctr	2	—	3	—	—	—	—	—	—	—	—	—	—	—
Loma Linda Univ	—	—	13	4	—	—	3	2	—	—	—	—	—	—
Loyola University	32	14	6	2	—	—	2	1	12	—	1	—	3	—
MAVERIC	—	—	—	—	—	—	5	3	6	—	—	—	—	—
MD Anderson CC	—	49	3	—	—	—	—	—	3	—	—	1	—	—
MUSC MU-NCORP	1	—	12	1	—	—	—	—	—	—	—	—	1	2
Madigan Army Med Ctr	3	—	1	—	—	—	—	31	4	—	—	—	—	—
Michigan CRC NCORP	20	—	13	2	—	—	—	—	2	—	—	—	—	—
Michigan, U of	34	—	17	—	2	—	—	—	—	—	1	—	—	—
Mississippi, Univ of	3	—	1	—	—	—	—	—	1	—	—	—	—	—
Montana NCORP	10	—	3	2	—	—	—	—	—	—	—	—	—	—
Nevada CRF NCORP	11	—	43	7	1	—	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	2	—	22	—	—	—	—	—	1	—	—	—	—	—
Northwest NCORP	13	—	4	—	—	—	—	16	10	—	—	—	—	—
Northwestern Univ	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Oklahoma, Univ of	6	—	11	3	—	—	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	1	—	1	—	—	—	—	—	—	—	—	—	—	—
Oregon Hlth Sci Univ	22	19	20	3	1	—	—	—	1	—	5	—	—	—
Ozarks NCORP	13	—	5	1	—	—	—	—	—	—	—	—	—	—
PCRC NCORP	33	—	7	—	—	—	—	4	1	—	—	—	—	—
Rochester, Univ of	14	1	6	5	—	—	6	11	2	—	—	—	2	11
San Antonio, U of TX	27	49	3	5	—	—	—	3	—	—	—	—	—	—
San Diego, U of CA	—	—	4	1	—	—	—	—	—	—	—	—	—	—
Scott & White CCOP	3	—	—	—	—	—	—	—	—	—	—	—	—	—
Scott & White Mem	2	—	—	—	—	—	—	—	—	—	—	—	—	—
So Calif, U of	9	150	30	7	—	1	11	—	4	—	1	—	1	—
Southeast COR NCORP	32	—	4	—	—	—	—	—	—	—	1	—	—	—
St Louis CCOP	4	—	—	—	—	—	—	—	—	—	—	—	—	—
St Louis University	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutter Cancer RC	23	—	5	—	—	—	1	—	2	—	—	—	—	1
Tennessee, U of	5	—	—	—	—	—	12	—	—	—	1	—	—	—
Upstate Carolina	1	—	1	—	—	—	—	—	3	—	—	—	—	—
Utah, U of	25	—	92	4	1	—	—	15	—	—	10	—	—	—
VAMC Kansas City	—	—	2	—	—	—	1	—	—	—	—	—	—	17
Wayne State Univ	15	—	—	1	1	—	8	—	4	—	—	—	1	—
Wichita NCORP	23	—	9	1	—	—	—	—	—	—	—	—	—	—
Wisconsin NCORP	1	—	1	—	—	—	—	—	—	—	—	—	—	—
Yale University	6	—	7	—	—	—	—	—	—	—	—	—	—	—
Alliance	297	105	226	33	4	—	—	—	—	—	—	—	—	—
CCTG	—	38	—	—	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	396	87	214	12	4	—	—	—	—	—	—	—	—	—
NRG	78	—	32	14	2	—	—	—	—	—	—	—	—	—
<b>Total</b>	<b>1,545</b>	<b>612</b>	<b>1,185</b>	<b>159</b>	<b>24</b>	<b>1</b>	<b>287</b>	<b>162</b>	<b>154</b>	<b>1</b>	<b>45</b>	<b>6</b>	<b>13</b>	<b>36</b>

# Leukemia Committee

## Leadership

Chair: ..... Harry P. Erba, M.D., Ph.D.  
 Vice-Chair: ..... Steven E. Coutre, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Megan Othus, Ph.D.  
 ..... Anna Moseley, M.S.

## Scientific Leadership

Translational Medicine: ..... Jerald P. Radich, M.D.  
 Pathology: ..... David R. Head, M.D.  
 Cytogenetics Liaison: ..... Diane Roulston, Ph.D.  
 ..... Min Fang, M.D., Ph.D.

## Designates

Data Coordinators: ..... Louise Highleyman  
 ..... Laura Kingsbury, M.R.T.  
 ..... Tracy Maher, C.C.R.P.  
 Oncology Research Professionals:  
 CRA: ..... TBD  
 Nurses: ..... Keisha C. Humphries, R.N., B.S.N.  
 ..... Mary Lynn Rush, R.N., B.S.N.  
 Patient Advocate: ..... Gail Sperling  
 Pharmaceutical Science: ..... Holly O. Chan, Pharm.D.  
 ..... Mai T. Nguyen, Pharm.D.  
 Protocol Coordinator: ..... Sandi Hita

## Time/Location

Friday, April 28, 2017 4:00 p.m. - 6:00 p.m.  
 Room: Bayview B (Bay Level)

## Introduction

## Presentation

## Leukemia Translational Medicine

Dr. Jerry Radich  
 Dr. Derek Stirewalt  
 Dr. Cecilia Yeung

**Leukemia Committee Updates:** Dr. Harry Erba

## AML/MDS Studies

### Active Studies

**S0919**, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Drs. Advani and Michaelis. Activated: 8/15/09.

**CTSU/E2905**, "Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alpha (Procrit®) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia." Dr. Schiffer. Activated by ECOG: 1/29/09; Activated by SWOG: 2/15/09.

### Proposed Studies

**S1612**, "A Randomized Phase II/III Trials of "Novel Therapeutic Regimens" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia Age 60 or Older." Drs. Michaelis and Walter.

**SXXXX**, "Optimization of Gemtuzumab Ozogamicin in Combination with Chemotherapy for Adults with Newly Diagnosed Favorable- or Intermediate-Risk Acute Myeloid Leukemia (AML): A Randomized Phase II Study." Dr. Walter.

### Closed Studies

**S1117**, "A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS)." Drs. Sekeres and List. Activated: 3/1/12. Closed: 11/14/14.

**CTSU/E2906**, "Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years)." Dr. Godwin. Activated by ECOG: 12/28/10; Activated by SWOG: 8/15/12. Closed: 2/23/15.

**S1203**, "A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. G. Garcia-Manero, J.M. Pagel, J.P. Radich, and M. Fang. Activated 12/15/12. Closed: 11/4/15.

# Leukemia Committee

## ALL Studies

### Active Studies

**S1318**, "A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients  $\geq$  65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL." Drs. Advani and O'Dwyer. Activated: 1/12/15.

**S1312**, "A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)." Drs. Advani and Liedtke. Activated: 4/1/14.

**CTSU/E1910**, "A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults." Dr. Liedtke. Activated by ECOG: 12/17/13. Activated by SWOG: 1/15/14.

### Closed Studies

**S0805**, "Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)." Drs. Ravandi, O'Brien, Forman, Ha, Wong, and Radich. Activated: 9/1/09. Closed: 10/1/13.

### Proposed Studies

**S1704**, "A Phase II Trial of PR-104 in Relapsed/Refractory Patients with T-cell Acute Lymphoblastic Leukemia." Drs. Advani and Stock.

**A041501**, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab ozogamicin (a conjugated anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 16-39 years) with Newly Diagnosed Precursor B-Cell ALL." Dr. Advani.

**CTSU/EXXXX**, "A Phase II Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab and Allo-HCT for Newly Diagnosed BCR-ABL-positive ALL in Adults." Drs. Phelan, Ofran, and Jamieson.

## CLL Studies

### Active Studies

**CTSU/E1912**, "A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. O'Brien. Activated by ECOG: 1/31/14; Activated by SWOG: 2/15/14.

### Closed Studies

**CTSU/A041202**, "A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ( $\geq$  65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Coutre. Activated by Alliance: 12/9/13; Activated by SWOG: 12/15/13.

## CML Studies

### Proposed Studies

**SXXXX**, "A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease." Dr. Sweet. (Formerly S1615)

Give to Hope –  
right from your phone

Text "SWOG" to 41444 to donate now

THE HOPE FOUNDATION

Because answers to cancers come from clinical trials



## Leukemia Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0919	S1203	S1312	S1318	A041202	E1910	E1912	E2905	E2906	NHLBIMDS
Arizona MC, U of	—	6	—	—	3	2	—	—	7	—
Arkansas, U of	—	—	—	—	1	2	8	—	—	—
Baptist MU-NCORP	—	—	—	—	1	—	—	—	—	—
Baylor College	5	2	4	—	—	—	—	—	—	—
Beaumont NCORP	—	—	—	—	—	—	6	—	—	—
Birmingham, U of AL	3	25	—	—	—	3	1	—	—	—
Boston Medical Ctr	—	—	—	—	2	—	—	—	—	—
CORA NCORP	—	—	—	—	2	—	1	1	—	—
CRC West MI NCORP	—	6	—	—	—	—	—	—	4	—
Cincinnati MC, U of	—	—	—	—	—	—	—	—	3	—
City of Hope Med Ctr	—	8	10	2	7	—	—	—	—	—
Cleveland Clinic OH	23	27	9	2	7	4	—	—	—	—
Colorado, U of	6	—	—	—	1	—	—	2	—	—
Columbia MU-NCORP	—	—	—	—	—	—	—	1	3	—
Columbia University	—	—	—	—	—	—	—	1	—	—
Columbus NCORP	—	—	—	—	1	—	—	—	—	—
Davis, U of CA	—	17	—	—	—	—	—	5	—	—
Dayton NCORP	—	6	—	—	—	—	—	—	5	—
Fred Hutchinson CRC	—	—	—	—	—	—	8	—	—	—
Greenville NCORP	—	—	—	—	—	1	1	6	—	—
Gulf South MU-NCORP	1	—	—	—	—	—	—	—	—	—
H Lee Moffitt CC	11	7	—	—	—	—	—	29	—	—
Harrington CC	—	—	—	—	—	—	1	—	—	—
Heartland NCORP	—	3	—	1	—	—	—	—	—	—
Henry Ford Hosp	—	—	—	—	—	1	—	1	—	—
Irvine, U of CA	—	8	—	—	2	3	1	—	—	—
Kaiser Perm NCORP	—	—	—	—	31	—	29	7	—	—
Kansas City NCORP	—	2	—	—	—	—	1	2	—	—
Kansas, U of	—	27	—	—	6	5	1	1	—	—
Kentucky, U of	—	12	—	—	—	—	—	—	7	—
Lahey Hosp & Med Ctr	—	—	—	—	2	—	2	—	—	—
Loma Linda Univ	—	—	—	1	—	—	—	—	—	—
Loyola University	4	10	—	—	—	—	3	—	9	—
MAVERIC	—	—	—	—	1	—	—	—	—	—



## Leukemia Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0919	S1203	S1312	S1318	A041202	E1910	E1912	E2905	E2906	NHLBIMDS
MD Anderson CC	—	5	—	—	—	—	—	—	—	—
MUSC MU-NCORP	—	13	—	—	—	—	—	—	—	—
Michigan CRC NCORP	—	1	—	—	—	—	—	—	—	—
Michigan, U of	—	2	—	1	—	—	—	—	—	—
Mississippi, Univ of	1	9	—	—	—	—	—	—	1	—
Montana NCORP	—	3	—	—	—	—	3	4	—	—
New Mexico MU-NCORP	5	4	—	1	—	—	—	—	1	—
Northwest NCORP	—	—	—	—	—	3	1	—	—	—
Northwestern Univ	—	4	—	—	2	1	2	—	—	—
Oklahoma, Univ of	—	9	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	—	—	—	—	3	—	1	—	—	—
Oregon Hlth Sci Univ	6	13	—	—	—	—	—	—	—	1
Ozarks NCORP	—	1	—	—	—	—	1	—	—	—
PCRC NCORP	2	7	—	—	1	—	1	1	—	—
Providence Hosp	—	4	—	—	—	—	1	2	—	—
Rochester, Univ of	15	22	6	1	10	4	24	3	27	—
San Antonio, U of TX	—	—	—	—	1	—	2	3	—	—
San Diego, U of CA	—	2	—	1	—	2	—	—	—	—
So Calif, U of	—	—	—	3	—	—	—	—	—	—
Southeast COR NCORP	—	1	—	—	—	—	—	1	—	—
Stanford University	24	47	2	—	6	6	21	1	—	—
Sutter Cancer RC	—	—	—	—	1	—	2	—	—	—
Tulane Univ MBCCOP	1	—	—	—	—	—	—	—	—	—
Tulane University	2	—	—	—	—	—	—	—	—	—
Upstate Carolina	—	3	—	—	—	—	—	—	3	—
Wayne State Univ	—	3	—	—	2	1	3	5	—	—
Wichita NCORP	6	—	—	—	—	—	—	—	—	—
Yale University	—	18	—	—	6	10	5	6	5	—
Alliance	—	218	—	6	—	—	—	—	—	—
CCTG	—	24	—	—	—	—	—	—	—	—
ECOG-ACRIN	—	162	—	3	—	—	—	—	—	—
NRG	—	13	—	—	—	—	—	—	—	—
<b>Total</b>	<b>115</b>	<b>754</b>	<b>31</b>	<b>22</b>	<b>99</b>	<b>48</b>	<b>130</b>	<b>81</b>	<b>75</b>	<b>1</b>



# Lung Committee

## Leadership

Chair: ..... Karen Kelly, M.D.  
 Vice-Chair: ..... Stephen G. Swisher, M.D.  
 Executive Officer: ..... Julie R. Gralow, M.D.  
 Statisticians: ..... Mary Redman, Ph.D.  
 ..... Jieling Miao, M.S.  
 ..... James Moon, M.S.  
 ..... Katherine Griffin, M.S.

## Scientific Leadership

Translational Medicine: ..... Philip C. Mack, Ph.D.  
 ..... Fred R. Hirsch, M.D., Ph.D.  
 Radiation Oncology: ..... Roy Decker, M.D.  
 Surgery: ..... Stephen G. Swisher, M.D.  
 Imaging: ..... Anthony F. Shields, M.D., Ph.D.  
 ..... Friedrich D. Knollmann, M.D., Ph.D.  
 Medical Oncology: ..... Karen Kelly, M.D.  
 Pathology: ..... Ignacio I. Wistuba, M.D.  
 Developmental Therapeutics: ..... Roy S. Herbst, M.D., Ph.D.  
 Early Therapeutics: ..... Shirish M. Gadgeel, M.D.

## Designates

Cancer Control Liaison: ..... Gary E. Goodman, M.D.  
 Community Affiliate: ..... Paul J. Hesketh, M.D.  
 Data Coordinators: ..... Krystle Pagarigan  
 ..... Louise Highleyman  
 ..... Larry Kaye  
 ..... Sarah Basse  
 Oncology Research Professionals:  
 CRAs: ..... Courtney L. Williamson  
 ..... Ginny M. Keeling, M.S.  
 Nurses: ..... Kimberly M. Belzer, M.S., P.A.C  
 ..... Rosalie Zablocki, R.N.  
 Patient Advocate: ..... Judy Johnson  
 Pharmaceutical Science: ..... Joyce Lee, Pharm.D.  
 ..... Linda Lee-Gabel, Pharm.D.  
 Protocol Coordinator: ..... Dawne Wenzel, M.A., M.S.  
 ..... Crystal Miwa (Lung-MAP Protocol)

## Time/Location

Thursday, April 27, 2017 4:45 p.m. - 7:45 p.m.

Room: Bayview Room (Bay Level)

**4:45 pm:** Opening Remarks and General Update – Dr. Kelly

**4:50 pm:** Thoracic Surgery Session – Dr. Swisher

- Update on Current Trials and Review of Trials in Development

**5:05 pm:** Thoracic Radiation Session – Dr. Decker

- Update on Current Trials and Review of Trials in Development

**5:30 pm:** Translational Medicine Session – Dr. Hirsh & Dr. Mack

- Update

**6:00 pm:** Thoracic Oncology Session

Scientific Presentations:

- SCLC: New concepts for novel therapeutics. Ravi Salgia MD, PhD. Professor and Chair of Medical Oncology. City of Hope Comprehensive Cancer Center Duarte, CA
- DNA damage repair inhibitors and immunotherapy as therapeutic approaches for SCLC. John Heymach MD, PhD. Professor and Chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center Houston, TX

**6:45 pm:** NSCLC

- Update on Current Trials and Review of Trials in Development  
Small Cell Lung Cancer
- Update on Current Trials and Review of Trials in Development  
Mesothelioma
- Update on Current Trials and Review of Trials in Development  
Thymic Carcinoma
- Review of Trial in Development

## Active Studies

**S1507,** “A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies.” Drs. Gadgeel, Riess and Mack. Activated: 7/17/16.

**S1403,** “A Randomized Phase II/III Trial of Afatinib Plus Cetuximab versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC).” Drs. Goldberg, Lilenbaum and Politi. Activated: 3/25/15.

**S1400,** “A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer.” Drs. Papadimitrakopoulou, Hirsch, Herbst, Schwartz, Gandara and Mack. Activated: 6/16/14.



# Lung Committee

**S1400G**, “A Phase II Randomized Study of Talazoparib for Previously-Treated Homologous Recombination Repair Deficiency Positive Patients with Squamous Cell Lung Cancer (Lung-MAP Sub-study).” Drs. Owonikoko and Byers.

**S1400I**, “A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-study).” Drs. Gettinger and Bazhenova. Activated: 12/18/15.

**S1206 (8811)**, “A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811).” Drs. Argiris, Cristea and Chen. Activated: 10/1/12; Phase II open: 7/15/16.

**S1204**, “A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients.” Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated: 8/29/13.

**S1013**, “A Prospective Study of Epidermal Growth Factor Receptor (Her-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFR 18 (FACT-EGFR 18) Questionnaire for EGFR-induced Skin Toxicities.” Drs. Wong and Wade. Activated: 11/15/11.

**CTSU/EAY131**, “Molecular Analysis for Therapy Choice (MATCH).” Drs. Villalobos, Lieu and Noel. Activated: 8/12/15; Temporarily closed: 11/11/15. Reactivated: 7/27/16.

**CTSU/A151216**, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activated: 8/18/14.

**CTSU/A081105**, “Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Kelly. Activated: 8/18/14.

**CTSU/EA5142**, “A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.” Dr. Chaft. Activated: 5/16/16.

**CTSU/NRGCC003**, “Randomized Phase II/III Trial Of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance For Small Cell Lung Cancer.” Dr. Gondi. Activated: 12/7/16.

**CTSU/E4512**, “A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.” Dr. Li. Activated: 8/18/14.

**CTSU/R1306**, “A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.” Drs. Tsao and Daly. Activated: 11/4/13.

**CTSU/CALGB 30610**, “Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.” Drs. Gadgeel and Gaspar. Activated: 3/15/08.

## Proposed Studies

**S1701**, “A Phase II Trial of Carboplatin, Paclitaxel, and Ramucirumab in Patients with Locally Advanced, Metastatic, or Recurrent Thymic Epithelial Tumors (TET) not Amenable to Curative Intent Surgery.” Dr. Tsao.

**S1619**, “A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Resectable Malignant Pleural Mesothelioma.” Dr. Tsao.

**S1400F**, “A Phase II Study of MEDI4736 Plus Tremelimumab as Therapy for Previously Treated Check-point Inhibitor Refractory Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study).” Drs. Leighl and Rizvi.

**EA5163/S1709**, “A Randomized Phase III Study for PD-L1 Positive Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Pembrolizumab in Induction or Maintenance Therapy with Immunosignature-Driven Analysis.” Drs. Chiang and Borghaei.

“Phase III Study of Pembrolizumab (MK-3475) vs. Gemcitabine for Second Line Treatment of Malignant Pleural Mesothelioma.” Drs. Garland and Verschraegen.

“Randomized Phase II Trial to Test the Efficacy of Nintedanib in Combination with Cisplatin and Etoposide for Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer.” Dr. Heymach and Dr. Chae.

“A Phase II Study of Pembrolizumab Concurrent with Radiotherapy Followed By Pembrolizumab Maintenance in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC) With Borderline Performance Status.” Drs. Aljumaily and Mitin. Mentors: Drs. Decker and Wozniack.

“A Randomized Phase II Study of Irinotecan versus Irinotecan plus Atezolizumab in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC).” Drs. Karim and Reckamp.

# Lung Committee

## Closed Studies

**S1400B**, “A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study).” Drs. Langer and Wade. Closed: 12/12/16.

**S1400C**, “A Phase II Study of Palbociclib for Previously Treated Cell Cycle

Gene Alteration Positive Pa-tients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study).” Drs. Edelman and Albain. Closed: 9/1/16.

**S1400D**, “A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer. (Lung-MAP Sub-study).” Drs. Aggarwal and Lara. Closed: 10/31/16.

## Lung Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0905	S1206	S1300	S1400	S1400A	S1400B	S1400C	S1400D	S1400I	S1403	S1507	A081105	A151216	C140503	C30607	C30610	C30901	E2511	E4512	EA5142	NRGCC003	R1306
Arizona MC, U of	—	3	—	1	1	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Arkansas, U of	2	—	—	2	—	—	—	1	—	—	—	—	—	1	—	2	—	—	—	—	—	—
Baptist MU-NCORP	—	—	—	10	1	—	1	—	4	—	—	—	10	—	—	—	—	—	—	—	—	—
Beaumont NCORP	—	—	—	2	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Boston Medical Ctr	—	—	—	4	—	—	—	—	1	—	—	—	2	—	—	—	—	—	—	—	—	—
Brooke Army Med Ctr	—	—	—	5	—	—	—	—	2	—	—	—	3	—	—	—	—	—	—	—	—	—
CORA NCORP	—	—	—	6	—	1	1	—	1	—	—	—	2	—	—	—	—	—	—	—	—	—
CRC West MI NCORP	—	—	—	7	2	—	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—
Carle CC NCORP	—	—	—	3	—	—	—	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Cincinnati MC, U of	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—
City of Hope Med Ctr	—	2	—	12	3	—	1	—	1	—	—	—	2	—	—	—	—	—	—	—	—	—
Cleveland Clinic OH	—	—	—	9	1	—	—	—	—	—	—	2	6	—	—	—	1	—	—	—	—	—
Colorado, U of	—	—	1	1	—	—	1	—	—	—	—	2	8	12	—	—	—	—	—	—	—	1
Columbia MU-NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Columbus NCORP	—	—	—	11	1	2	1	—	1	1	—	—	—	—	—	1	—	—	—	—	—	—
Cookeville Reg MC	—	—	—	9	3	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Davis, U of CA	1	7	—	12	2	—	2	—	3	4	1	—	11	6	—	11	—	—	1	—	—	—
Dayton NCORP	—	—	—	2	—	—	—	—	—	1	—	—	1	—	—	—	—	—	—	1	—	—
Essentia Hlth NCORP	—	—	—	6	—	—	2	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Franciscan Res Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fred Hutchinson CRC	—	—	—	17	—	1	1	—	3	—	—	—	3	—	—	—	—	—	—	—	—	—
Georgia NCORP	2	—	—	4	—	—	—	—	3	—	1	—	—	—	—	1	—	—	—	—	—	—
Greenville NCOR	2	—	—	9	1	1	—	1	2	2	—	—	—	—	—	—	—	—	—	—	—	—
Gulf South MU-NCORP	—	—	—	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
H Lee Moffitt CC	—	—	—	5	—	—	—	—	—	—	—	—	9	—	—	—	—	—	—	—	—	—
Harrington CC	—	—	—	5	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Harrison Medical Ctr	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hawaii MU-NCORP	—	1	—	5	2	—	—	—	1	3	—	—	—	—	—	—	—	2	—	—	—	—
Heartland NCORP	8	1	—	36	4	—	2	1	4	1	—	—	—	—	—	2	7	—	—	—	—	—
Henry Ford Hosp	3	2	—	6	1	1	—	—	—	—	—	1	11	—	—	—	—	—	—	1	—	—
Irvine, U of CA	—	—	—	7	1	—	—	—	1	—	—	2	4	—	—	—	—	—	—	—	—	—
Kaiser Perm NCORP	8	—	—	34	4	—	4	1	4	15	—	6	71	—	—	2	—	—	1	—	—	—
Kansas City NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kansas, U of	1	—	—	28	3	—	—	—	8	—	—	—	14	—	—	1	—	—	—	—	—	—
Kentucky, U of	—	—	—	7	1	—	—	1	3	—	—	—	—	—	—	—	—	—	—	—	—	—
Lahey Hosp & Med Ctr	—	1	—	8	2	—	1	—	1	2	—	—	6	—	—	—	—	—	—	1	—	2
Loma Linda Univ	—	—	—	2	1	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Loyola University	—	1	—	8	—	—	1	—	3	—	—	—	2	—	—	—	—	—	—	2	—	—
MAVERIC	—	—	—	10	—	—	1	2	—	4	—	—	—	—	—	—	—	—	—	—	—	—

# Let's Make More Time



## Lung Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S0905	S1206	S1300	S1400	S1400A	S1400B	S1400C	S1400D	S1400I	S1403	S1507	A081105	A151216	C140503	C30607	C30610	C30901	E2511	E4512	EA5142	NRGCC003	R1306
MD Anderson CC	55	2	—	10	4	—	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	5
MUSC MU-NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—
Methodist Hospital	—	—	—	4	—	—	—	—	—	—	—	—	4	—	—	—	—	—	—	—	—	—
Michigan CRC NCORP	4	—	—	19	5	2	—	1	1	1	—	—	—	—	—	—	—	—	—	—	—	—
Michigan, U of	7	—	—	9	2	1	2	—	2	3	—	—	28	—	—	1	—	—	—	—	—	—
Mississippi, Univ of	4	—	—	5	—	1	—	—	2	—	—	—	3	—	—	1	—	—	—	—	—	—
Montana NCORP	5	—	—	11	2	1	2	—	1	1	—	—	—	—	—	—	—	2	—	—	—	—
Nevada CRF NCORP	—	—	—	4	—	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—	—
New Mexico MU-NCORP	—	—	—	4	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—
Northwest NCORP	—	—	—	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Northwestern Univ	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oklahoma, Univ of	—	—	—	8	—	—	—	1	2	3	—	—	—	—	—	—	—	—	—	—	—	—
Orange Reg Med Ctr	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—
Oregon Hlth Sci Univ	—	—	—	5	1	—	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—	—
Ozarks NCORP	—	—	—	14	1	—	1	1	2	1	1	—	—	—	—	—	—	—	—	—	—	—
PCRC NCORP	2	—	—	10	3	1	—	—	—	—	—	—	4	6	—	—	—	—	—	—	—	—
Providence Hosp	—	—	—	8	2	—	—	—	—	—	—	—	7	—	—	2	—	—	1	—	—	—
Rochester, Univ of	—	—	—	14	2	—	1	—	1	—	—	—	—	—	—	—	—	—	—	—	1	—
San Antonio, U of TX	—	—	—	10	—	1	1	3	2	3	—	—	—	—	—	3	—	—	—	—	—	—
San Diego, U of CA	—	—	—	7	1	—	—	—	1	2	—	—	2	—	—	—	—	—	—	—	—	—
So Calif, U of	3	—	—	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—	—	—
Southeast COR NCORP	3	—	—	29	1	1	—	1	7	1	—	—	—	—	—	—	—	4	—	—	—	—
Sutter Cancer RC	—	—	—	2	—	—	—	—	—	—	—	1	4	—	—	—	—	—	—	1	—	—
Tennessee, U of	—	—	—	—	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—	—
Tulane Univ MBCCOP	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Univ of Louisville	—	—	—	—	—	—	—	—	—	—	—	—	4	—	—	—	—	—	—	—	—	—
Upstate Carolina	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Utah, U of	—	—	—	1	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
VAMC Kansas City	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Wayne State Univ	5	—	—	7	2	—	—	—	—	1	—	—	1	—	—	1	—	—	—	—	—	—
Wichita NCORP	—	—	—	19	2	—	—	—	3	4	—	—	—	—	—	13	—	—	—	—	—	—
Wisconsin NCORP	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Yale University	—	7	—	18	2	—	1	1	—	11	—	—	4	—	—	—	—	—	—	—	—	—
Alliance	—	—	—	247	16	12	12	10	27	11	3	—	—	—	—	—	—	—	—	—	—	—
CCTG	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ECOG-ACRIN	—	—	—	239	15	6	5	10	40	6	6	—	—	—	—	—	—	—	—	—	—	—
NRG	—	—	—	130	19	6	5	6	13	5	—	—	—	—	—	—	—	—	—	—	—	—
Total	117	27	1	1,151	116	39	53	43	165	85	13	14	229	27	2	50	2	8	3	6	1	8

# Lymphoma Committee

## Leadership

Chair: ..... Jonathan W. Friedberg, M.D.  
 Vice-Chair: ..... Sonali M. Smith, M.D.  
 Executive Officer: ..... Susan M. O'Brien, M.D.  
 Statisticians: ..... Michael LeBlanc, Ph.D.  
 ..... Hongli Li, M.S.  
 Scientific Leadership  
 Translational Medicine: ..... TBD  
 Radiation Oncology: ..... Louis S. Constine, M.D.  
 Imaging: ..... Oliver W. Press, M.D., Ph.D.  
 ..... Lawrence H. Schwartz, M.D.  
 Pathology: ..... Lisa M. Rimsza, M.D.  
 Early Therapeutics: ..... Daruka Mahadevan, M.D., Ph.D.  
 Designates  
 Cancer Control: ..... TBD  
 Data Coordinators: ..... Jeri Jardine  
 ..... Iris Syquia  
 Oncology Research Professionals:  
 CRA: ..... Erin M. Cebula, M.P.H.  
 Nurse: ..... TBD  
 Patient Advocate: ..... Hildy Dillon, M.P.H.  
 Pharmaceutical Science: ..... Lara M. Au, Pharm.D.  
 ..... Craig Elg, Pharm.D.  
 Protocol Coordinator: ..... TBD

## Time/Location

Saturday, April 29, 2017 9:30 a.m. - 12:30 p.m.  
 Room: Grand C (Street Level)

## Agenda

1. Report of Ongoing Studies: Dr. Stiff
2. Upcoming Trials
  - a. Follicular lymphoma (S1608): Dr. Barr
  - b. Mantle cell lymphoma: Dr. Till
3. Correlative Science Report from S0816 (Dr. Hsi)
4. Guest Speaker: Dr. Ash Alizadeh, MD, PhD, Stanford University
5. Monitoring patients with lymphoma after treatment: update: Dr. Phillips and Dr. S. Smith

## Non-Hodgkin Lymphoma

**S1001**, "A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)," Drs. Persky, Constine, Rimsza, and Fitzgerald. Activated: 7/18/11.

**CTSU/E1411**, "Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation (RB -->R); Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV--> R), Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB --> LR) or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation (RBV --> LR)." Dr. Till. Activated: 5/22/12. Closed: 9/9/16.

**CTSU/E1412**, "Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diag-nosed Diffuse Large B Cell Lymphoma." Dr. Amengual. Activated: 6/1/14.

**CTSU/9177**, "Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma." Dr. Fanale. Activated: 4/13/12.

**CTSU/CALGB 51101**, "A Randomized Phase II Trial of Myeloablative versus Non-Myeloablative Consoli-dation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma." Dr. Mohile. Activated: 6/15/12.

**EAY 131**, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/15.

**CTSU/A051301**, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Dr. Stiff. Activated: 7/6/16.

## Cancer Control Studies

**S1204**, "A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients." Drs. Ramsey, Loomba, Chugh, Hershman and Hwang. Activated : 8/29/13.

## Studies in Development

**S1608**, "Randomized Phase II Trial in High-Risk Relapsed Refractory Follicular Lymphoma." Dr. Barr.



# Lymphoma Committee

## Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1001	C51101	E1411	E1412	9177
Arizona MC, U of	7	—	1	1	—
Arkansas, U of	—	—	1	—	—
Brooke Army Med Ctr	—	—	—	2	—
CRC West MI NCORP	—	—	3	—	—
Cincinnati MC, U of	—	—	—	3	—
City of Hope Med Ctr	4	—	—	—	—
Cleveland Clinic OH	—	—	9	—	4
Colorado, U of	—	—	4	—	—
Columbia MU-NCORP	—	—	1	3	—
Davis, U of CA	—	1	—	—	—
Dayton NCORP	—	—	2	—	—
Essentia Hlth NCORP	1	—	—	—	—
Fred Hutchinson CRC	2	2	4	—	—
Greenville NCORP	2	—	—	—	—
Hawaii MU-NCORP	4	—	4	1	—
Kaiser Perm NCORP	—	—	14	7	—
Kansas City NCORP	6	—	3	1	1
Kansas, U of	—	2	—	—	—
Kentucky, U of	3	—	—	—	4
Loyola University	5	—	—	—	—
Michigan CRC NCORP	8	—	—	—	—
Montana NCORP	1	—	3	4	—
Northwest NCORP	4	—	—	—	—
Oregon Hlth Sci Univ	—	—	6	—	—
PCRC NCORP	2	—	3	—	—
Rochester, Univ of	28	3	25	16	9
Southeast COR NCORP	1	—	1	—	—
Tennessee, U of	—	—	—	—	1
Tulane University	—	1	—	—	—
Upstate Carolina	7	—	1	—	—
Wayne State Univ	—	—	1	1	—
Wichita NCORP	6	—	—	—	—
Yale University	6	—	—	—	—
Alliance	40	—	—	—	—
ECOG-ACRIN	20	—	—	—	—
NRG	2	—	—	—	—
<b>Total</b>	<b>159</b>	<b>9</b>	<b>86</b>	<b>39</b>	<b>19</b>

# Melanoma Committee

## Leadership

Chair: .....Antoni Ribas, M.D., Ph.D.  
 Vice-Chair: .....William E. Carson, III, M.D.  
 Executive Officer: .....Christopher W. Ryan, M.D.  
 Statisticians: .....Michael Wu, Ph.D.  
 .....Megan Othus, Ph.D.  
 .....James Moon, M.S.  
 .....Hongli Li, M.S.

## Scientific Leadership

Translational Medicine: .....William E. Carson, III, M.D.  
 Radiation Oncology: .....Evan J. Wuthrick, M.D.  
 Surgery: .....Robert H.I. Andtbacka, M.D.  
 Imaging: .....Kenneth F. Grossman, M.D., Ph.D.  
 .....Martin Allen-Auerbach, M.D.  
 Medical Oncology: .....Lawrence E. Flaherty, M.D.  
 Pathology: .....TBD  
 Non-Melanoma Skin Cancer: .....Sancy A. Leachman, M.D., Ph.D.  
 Early Therapeutics: .....Jeffrey A. Sosman, M.D.  
 ECOG-ACRIN Liaison .....Kenneth F. Grossman, M.D., Ph.D.

## Designates

Cancer Control Liaison: .....Sancy Leachman, M.D., Ph.D.  
 Data Coordinator: .....Diana Heaney  
 .....Derek Salud  
 Oncology Research Professionals:  
 CRA: .....Kacie L. Simpson, B.S., C.C.R.P.  
 Nurse: .....Lisa S. Morgan, R.N., O.C.N.  
 Patient Advocate: .....Valerie Guild  
 Pharmaceutical Science: .....Sun "Coco" Yang, Pharm.D., Ph.D.  
 .....Mai T. Nguyen, Pharm.D.  
 Protocol Coordinator: .....Danae Campos

## Time/Location

Friday, April 28, 2017 9:30 a.m. - 11:30 a.m.  
 Room: Bayview B (Bay Level)

## Agenda

**9:30-10:15 am:** Scientific Presentation - J. William Harbour, MD, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine

**10:15-10:30 am:** Panel discussion

**10:30-11:30 am:** SWOG Melanoma Committee Clinical Trials

## Active Studies

**S1221**, "Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer." Drs. Algazi and Ribas. Activated: 7/1/13.

**S1320**, "A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma." Drs. Algazi and Lo. Activated: 7/22/14.

**S1404**, "A Phase III Randomized Trial Comparing High-Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma." Drs. Grossmann and Patel.

**S1512**, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Re-sectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan.

**CTSU/EA6134**, "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma". Dr. Chmielowski. Activated: 9/1/15.

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." Dr. Kim. Activated: 8/1/16.

## Upcoming Studies

**S1607**, "A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan.

**S1616**, "Combining Ipilimumab and Nivolumab in Advanced Melanoma Following Progression on a PD-1 Inhibitor Alone." Dr. VanderWalde.

## Melanoma Committee

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1221	S1320	S1404	E2607	E3612	EA6134	EA6141
Arizona MC, U of	—	2	4	—	—	—	—
Arkansas, U of	—	5	3	—	—	—	—
Baylor Univ Med Ctr	—	—	10	—	—	—	—
Boston Medical Ctr	—	1	—	—	—	—	—
CORA NCORP	—	1	4	—	—	—	—
CRC West MI NCORP	—	1	10	—	—	—	—
Cedars-Sinai Med Ctr	—	—	7	—	—	—	—
Cincinnati MC, U of	—	—	3	—	—	—	—
City of Hope Med Ctr	—	—	7	—	—	—	1
Cleveland Clinic OH	—	—	13	—	—	—	—
Colorado, U of	5	2	21	—	—	1	—
Columbia MU-NCORP	—	—	1	—	—	—	—
Columbus NCORP	—	—	4	—	—	—	—
Davis, U of CA	—	—	1	—	—	—	—
Dayton NCORP	—	—	6	—	—	—	—
Georgia NCORP	—	—	10	—	—	—	—
Greenville NCORP	—	—	—	—	1	—	—
Gulf South MU-NCORP	—	—	1	—	—	—	—
H Lee Moffitt CC	—	—	26	—	—	—	—
Hawaii MU-NCORP	—	—	—	2	—	—	—
Heartland NCORP	—	3	12	—	—	—	—
Irvine, U of CA	—	—	—	1	—	—	—
Kaiser Perm NCORP	—	18	34	—	3	2	10
Kansas City NCORP	—	—	—	1	—	—	1
Kansas, U of	—	5	13	—	—	2	—
Lahey Hosp & Med Ctr	—	1	4	—	—	—	—
Los Angeles, U of CA	6	2	12	—	—	3	—
Loyola University	—	4	—	—	—	—	—
MD Anderson CC	—	—	23	—	—	—	—
Michigan CRC NCORP	—	—	1	—	—	—	—



## Melanoma Committee, cont.

### Cumulative Accrual by Institution and Study

For the Period Ending January 31, 2017 | Currently Open Studies or Studies Closed after July 1, 2015

	S1221	S1320	S1404	E2607	E3612	EA6134	EA6141
Michigan, U of	5	2	10	1	—	—	—
Mississippi, Univ of	—	—	1	—	—	—	—
Montana NCORP	—	—	2	—	—	—	—
Mt Sinai Med Ctr	—	—	3	—	—	—	—
Nevada CRF NCORP	—	1	—	—	—	—	—
New Mexico MU-NCORP	—	—	6	—	—	—	—
Northwest NCORP	—	—	4	—	—	—	—
Northwestern Univ	—	—	8	—	1	—	—
Ohio State Univ	6	6	22	—	—	1	—
Oregon Hlth Sci Univ	—	—	6	—	—	—	—
Ozarks NCORP	—	2	2	—	—	—	—
PCRC NCORP	2	2	7	—	—	—	—
Rochester, Univ of	—	1	4	—	—	—	—
San Antonio, U of TX	—	—	3	—	—	—	1
San Diego, U of CA	—	—	4	—	—	—	—
San Francisco, U-CA	1	8	—	—	—	—	—
Southeast COR NCORP	—	4	5	—	—	—	—
Sutter Cancer RC	2	—	2	—	—	2	3
Tennessee, U of	—	—	1	—	—	—	—
Utah, U of	—	5	22	—	—	—	—
VAMC Kansas City	—	—	1	—	—	—	—
Wayne State Univ	—	—	4	—	—	2	—
Wichita NCORP	—	2	6	—	—	—	—
Wisconsin NCORP	—	—	2	—	—	—	—
Yale University	—	—	2	—	—	—	—
Alliance	—	10	91	—	—	—	—
CCTG	—	—	45	—	—	—	—
ECOG-ACRIN	—	35	162	—	—	—	—
NRG	—	7	51	—	—	—	—
<b>Total</b>	<b>27</b>	<b>130</b>	<b>706</b>	<b>5</b>	<b>5</b>	<b>13</b>	<b>16</b>





# Publication List by Committee

The publications listed below were received by the group chair's office as published, accepted, and submitted or reflect change in publication status since the SWOG 2016 Fall Group Meeting. Not included are submitted or accepted publications where posting is not permitted due to journal embargo policy (e.g., NEJM). Conference abstracts are also not included.

## Adolescent and Young Adult (AYA) Committee

No publication information for this cycle.

## Barlogie-Salmon Myeloma Committee

### Published/Accepted Manuscripts

**S0777** Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without Intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open label, phase 3 trial. BGM Durie, A Hoering, MH Abidi, SV Rajkumar, MD, J Epstein, S Kahanic, M Thakuri, F Reu, C Reynolds, R Sexton, R Orlowski, B Barlogie, A Dispenzieri. *Lancet* 2017 Feb 4;389(10068):519-527. PMID28017406 <https://www.ncbi.nlm.nih.gov/pubmed/28017406>

**S0120** MGUS to myeloma: a mysterious gammopathy of underexplored significance. MV Dhodapkar. *Blood* 128:2599-2606, 2016. [Perspectives] PMID27737890; PMC5146746 <https://www.ncbi.nlm.nih.gov/pubmed/27737890>

### Submitted Manuscripts

No publication information for this cycle.

## Breast Committee

### Published/Accepted Manuscripts

**S1416** Breast cancer outlook for 2017: keeping the accelerator to the floor. VK Gadi, JR Gralow. *Oncology (Williston Park)* 30(12 suppl 2):1-2, 2016 [Review]. PMID: 27933601. <https://www.ncbi.nlm.nih.gov/pubmed/27933601>

**S9630** A phase III randomized comparison of medroxyprogesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630. RK Potkul, JM Unger, RB Livingston, S Wilczynski, C Salomon, B Smith, L Wong, DL Campbell, SJ Vogel, GL Anderson, GE Goodman, PH Brown, FL Meyskens, KS Albain. *NPJ Breast Cancer*, (2016) 16024, p. 1-5. [also under Prevention Committee]. Journal link: <http://www.nature.com/articles/npjbcancer201624>

**S9630/Multiple Studies** How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albain, DL Hershman, JM Unger, SS Lo. *NPJ Breast Cancer*, [commentary] accepted. [also under Prevention Committee]

**C40601** Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). M Golshan, CT Cirincione, WM Sikov, LA Carey, DA Berry, B Overmoyer, NL Henry, G Somlo, E Port, HJ Burstein, C Hudis, E Winer, DW Ollila. *Breast Cancer Research and Treatment* Nov 2016, 160 (2):297-304. PMID27704226; PMC5189982. <https://www.ncbi.nlm.nih.gov/pubmed/27704226>

### Submitted Manuscripts

**S0221** Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. *Journal of the National Cancer Institute*, under revision/pending resubmission. [see also SCQOL committee]

## Cancer Control & Prevention

## Cancer Care Delivery Committee

### Published/Accepted Manuscripts

**S9217** Long-term consequences of intervention following receipt of finasteride or placebo in the Prostate Cancer Prevention Trial (SWOG S9217). J Unger, C Till, I Thompson, C Tangen, P Goodman, J Wright, W Barlow, S Ramsey, L Minasian, D Hershman. *Journal of the National Cancer Institute*, Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168. PMID27565902 <http://www.ncbi.nlm.nih.gov/pubmed/27565902>

**Multiple Studies\*** The impact of SWOG treatment trials on population survival. JM Unger, M LeBlanc, CD Blanke. *JAMA Oncology*, in press. [\*studies: SWG01, SWG02, S7436, S7704, S7817, S8494, S8501, S8591, S8624, S8710, S8736, S8797, S8814, S8892, S8897, S8949, S9008, S9126, S9210, S9308, S9916, S0226, S0777]

# Publication List by Committee

**Multiple/Other** Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. HH Pang, X Wang, T Stinchcombe, M Wong, P Cheng, A Kishor Ganti, D Sargent, Y Zhang, C Hu, S Mandrekar, M Redman, J Manola, R Schilsky, H Cohen, J Bradley, A Adjei, D Gandara, S Ramalingam, E Vokes. *Journal of Clinical Oncology* 2016 Sep 19 [Epub ahead of print]. PMID27646951 [also under Lung Committee] <https://www.ncbi.nlm.nih.gov/pubmed/27646951>

Characterizing 18 years of death with dignity in Oregon. C Blanke, M LeBlanc, D Hershman, L Ellis, F Meyskens. *JAMA Oncology*, in press.

Words matter: restoring respect and dignity when referring to people with cancer. LM Ellis, CD Blanke, E Kohn. *Cancer* 2017 Feb 9. doi: 10.1002/cncr.30625. [Epub ahead of print]. PMID28182266 <https://www.ncbi.nlm.nih.gov/pubmed/28182266>

Feasibility of a centralized clinical trials coverage analysis: a joint initiative of the American Society for Clinical Oncology (ASCO) and the National Cancer Institute (NCI). CM Szczepanek, P Hurley, MJ Good, A Denicoff, K Willenberg, C Dawson, D Kurbegov. *Journal of Oncology Practice*, in press.

## Submitted Manuscripts

**S0000/S9217** The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. JM Unger, WE Barlow, CM Tangen, SD Ramsey, IM Thompson, Jr., EA Klein, M LeBlanc, CD Blanke, PJ Goodman, LM Minasian, DL Hershman. *Cancer*, under review.

**S1415CD** A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy (SWOG S1415CD): The TrACER study. A Bansal, SD Sullivan, DL Hershman, GH Lyman, WE Barlow, JS McCune, SD Ramsey. *Journal of Comparative Effectiveness Research*, under review.

**Multiple Studies\*** Survival by Hispanic ethnicity among SWOG cancer clinical trials patients. M Chavez-MacGregor, JM Unger, A Moseley, S Ramsey, DL Hershman. *JAMA Oncology*, submitted. [\*studies: S8516, S8600, S8809, S8814, S8894, S8897, S8905, S9008, S9031, S9125, S9210, S9240, S9304, S9308, S9313, S9321, S9333, S9346, S9349, S9415, S9420, S9509, S9623, S9704, S9800, S9911, S9916, S0003, S0012, S0016, S0033, S0106, S0221, S0226, S0232, S0307, S0421, S0500].

## Cancer Survivorship Committee

### Published/Accepted Manuscripts

**S9346** Adverse health effects of intermittent vs continuous androgen deprivation therapy for metastatic prostate cancer - Reply. DL Hershman,

JM Unger. *JAMA Oncology* 2016 May 1;2(5):686-687. PMID27244679 <https://www.ncbi.nlm.nih.gov/pubmed/27244679>

**Multiple Studies** Association between body mass index (BMI) and cancer survival in a pooled analysis of 22 trials. H Greenlee, J Unger, M LeBlanc, S Ramsey, D Hershman. *Cancer Epidemiology, Biomarkers & Prevention*, 2017 Jan;26(1):21-29. PMID27986655 <https://www.ncbi.nlm.nih.gov/pubmed/27986655>

**N0147** Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance). P Singh, Q Shi, N Foster, A Grothey, S Nair, E Chane, A Shields, R Goldberg, S Gill, M Kahlenberg, F Sinicrope, D Sargent, SR Alberts. *Oncologist* 2016 Dec;21(12):1509-1521. PMID27881709; PMC5153338. [also under GI Committee] <https://www.ncbi.nlm.nih.gov/pubmed/27881709>

## Submitted Manuscripts

No publication information for this cycle.

## Prevention & Epidemiology Committee

### Published/Accepted Manuscripts

**S0000** A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci. KA Rand, C Song, E Dean, D Serie, K Curtin, D Hazelett, X Sheng, D Hu, CA Huff, L Bernal-Mizrachi, MH Tomasson, S Ailawadhi, S Singhal, K Pawlish, E Peters, C Bock, A Stram, D Van Den Berg, CK Edlund, DV Conti, T Zimmerman, A Hwang, S Huntsman, J Graff, A Nooka, S Pregia, S Berndt, WJ Blot, J Carpten, G Casey, L Chu, WR Diver, VL Stevens, M Lieber, P Goodman, AJM Hennis, AW Hsing, J Mehta, RA Kittles, S Kolb, EA Klein, C Leske, A Murphy, B Nemesure, C Neslund-Dudas, C Pettaway, R Vij, JL Rodriguez-Gil, BA Rybicki, JL Stanford, LB Signorello, A Nooka, S Strom, JS Witte, J Xu, SL Zheng, SY Wu, Y Yamamura, M Gebregziabher, CB Ambrosone, P Bhatti, EM John, L Bernstein, W Zheng, AF Olshan, JJ Hu, RG Ziegler, S Nyante, EV Bandera, BM Birmann, SA Ingles, MF Press, M Zangari, T Martin, G Tricot, S Kumar, J Wolf, SL Deming, RK Severson, N Rothman, AR Brooks-Wilson, V Rajkumar, LN Kolonel, SJ Chanock, S Slager, N Janakiraman, H Tolebero, EE Brown, A DeRoos, A Mohrbacher, GA Colditz, BE Henderson, GG Giles, JJ Spinelli, B Chiu, N Munshi, KC Anderson, J Zonder, RZ Orłowski, S Lonial, N Camp, C Vachon, E Ziv, DO Stram, CA Haiman, W Cozen. *Cancer Epidemiology, Biomarkers & Prevention*, 2016 Dec;25(12):1609-1618 2016 Sep 1. PMID27587788 <https://www.ncbi.nlm.nih.gov/pubmed/27587788>

# Publication List by Committee

**S0000** Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. M Zhang, Z Wang, O Obazee, J Jia, E Childs, J Hoskins, G Figlioli, E Mocci, I Collins, CC Chung, C Hautman, AA Arslan, L Beane-Freeman, PM Bracci, J Buring, EJ Duell, S Gallinger, GG Giles, GE Goodman, PJ Goodman, A Kaminen, LN Kolonel, MH Kulke, N Malats, SH Olson, HD Sesso, K Visvanathan, E White, W Zheng, CC Abnet, D Albanes, G Andreotti, MA Austin, H Bas Bueno-de-Mesquita, D Basso, SI Berndt, M-C Boutron-Ruault, M Bijlsma, H Brenner, L Burdette, D Campa, NE Caporaso, G Capurso, GM Cavestro, M Cotterchio, E Costello, J Elena, U Boggi, JM Gaziano, M Gazouli, EL Giovannucci, M Goggins, MJ Gorman, M Gross, CA Haiman, M Hassan, KJ Helzlsouer, N Hu, DJ Hunter, E Iskierka-Jazdzewska, M Jenab, R Kaaks, TJ Key, K Khaw, EA Klein, M Kogevinas, V Krogh, J Kupcinskas, RC Kurtz, MT Landi, S Landi, L Le Marchand, A Mambrini, S Mannisto, RL Milne, R Neale, AL Oberg, S Panico, AV Patel, P Peeters, U Peters, R Pezzilli, F Tavano, M Porta, M Purdue, J Ramón Quiros, Elio Riboli, N Rothman, A Scarpa, G Scelo, X Shu, DT Silverman, P Soucek, O Strobel, M Sund, E Malecka-Panas, PR Taylor, RC Travis, M Thornquist, A Tjønneland, GS Tobias, D Trichopoulos, Y Vashist, P Vodicka, J Wactawski-Wende, N Wentzensen, H Yu, K Yu, A Zeleniuch-Jacquotte, C Kooperberg, HA Risch, EJ Jacobs, D Li, C Fuchs, R Hoover, P Hartge, SJ Chanock, GM Petersen, RS Stolzenberg-Solomon, BM Wolpin, P Kraft, AP Klein, F Canzian, LT Amundadottir. *Oncotarget*, 2016 Oct 11;7(41):66328-66343. PMID27579533 <https://www.ncbi.nlm.nih.gov/pubmed/27579533>

**S0000** The opportunities and challenges of ancillary studies into a cancer prevention randomized clinical trial. PJ Goodman, CM Tangen, AK Darke, KB Arnold, JA Hartline, M Yee, K Anderson, A Caban-Holt, WG Christen, PA Cassano, P Lance, EA Klein, JJ Crowley, LM Minasian, FL Meyskens. *Trials*, 17:400, 2016. PMID27519183; PMC4983010. <http://www.ncbi.nlm.nih.gov/pubmed/27519183>

**S0000A** PREADViSE: Outcomes from the Prevention of Alzheimer's Disease by Vitamin E and Selenium trial. RJ Kryscio, EL Abner, AI Caban-Holt, M Lovell, P Goodman, AK Darke, M Yee, J Crowley, FA Schmitt. *JAMA*, in press.

**S0000A** Self-reported sleep apnea and dementia risk: Findings from The Prevention of Alzheimer's Disease Alzheimer's Disease with Vitamin E and Selenium Trial. X Ding, RJ Kryscio, JK Turner, GA Jicha, GE Cooper, A Caban-Holt, F Schmitt, E Abner. *Journal of the American Geriatrics Society*, 2016 Dec;64(12):2472-2478. PMID27801937; PMC5173398 <https://www.ncbi.nlm.nih.gov/pubmed/27801937>

**S0000D** Colorectal adenomas in participants of the SELECT randomized trial of Selenium and Vitamin E for Prostate Cancer Prevention. P Lance,

DS Alberts, PA Thompson, L Fales, F Wang, J San Jose, ET Jacobs, PJ Goodman, AK Darke, M Yee, L Minasian, IM Thompson, DJ Roe. *Cancer Prevention Research*, 2017 Jan;10(1):45-54. PMID2777235 <https://www.ncbi.nlm.nih.gov/pubmed/2777235>.

**S0000/S9217** Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors. Results from two large randomized clinical trials. CM Tangen, PJ Goodman, C Till, J Schenk, M Scott Lucia, Ian M. Thompson. *Journal of Clinical Oncology*, 2016 Dec 20;34(36):4338-4344. PMID: 27998216 <https://www.ncbi.nlm.nih.gov/pubmed/27998216>

**S1119** Antibiotic resistance among *Helicobacter pylori* clinical isolates in Lima, Peru (SWOG Clinical Trial 1119). KF Boehnke, M Valdivieso, A Bussalleu, R Sexton, K Thompson, S Osorio, I Novoa Reyes, JJ Crowley, LH Baker, C Xi. *Infection and Drug Resistance*, 2017 10:85-90. Journal link: [file:///C:/Users/arlauskp/Downloads/IDR-123798-antibiotic-resistance-among-helicobacter-pylori-clinical-iso\\_031017.pdf](file:///C:/Users/arlauskp/Downloads/IDR-123798-antibiotic-resistance-among-helicobacter-pylori-clinical-iso_031017.pdf)

**S1119** Clinical, epidemiologic, and genomic studies (SWOG S1119) of *Helicobacter pylori* in Lima, Peru: role of contaminated water. M Valdivieso, A Bussalleu, R Sexton, K Boehnke, S Osorio, I Novoa Reyes, JJ Crowley, GE Goodman, LH Baker, C Xi. *Journal of Cancerology (Journal of the National Cancer Institute of Mexico)* April-June 3(2):52-63, 2016. ISBN 2462-4136. Journal link: <http://www.journalofcancerology.com/sumarios.asp?anyvol=201603&num=2>

**S9217** Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. D Winchester, C Till, PJ Goodman, CM Tangen, RM Santella, TL Johnson-Pais, RJ Leach, J Xu, SL Zheng, IM Thompson, MS Lucia, SM Lippman, HL Parnes, WB Isaacs, AM De Marzo, CG Drake, EA Platz. *Prostate*, in press.

**S9630** A phase III randomized comparison of medroxyprogesterone acetate versus observation for the prevention of endometrial pathology in postmenopausal patients with breast cancer treated with adjuvant tamoxifen: SWOG S9630. RK Potkul, JM Unger, RB Livingston, S Wilczynski, C Salomon, B Smith, L Wong, DL Campbell, SJ Vogel, GL Anderson, GE Goodman, PH Brown, FL Meyskens, KS Albain. *NPJ Breast Cancer*, (2016) 16024, p. 1-5. [also under Breast Committee]. Journal link: <http://www.nature.com/articles/npjbcancer201624>

**S9630/Multiple** How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? KD Crew, KS Albain, DL Hershman, JM Unger, SS Lo. *NPJ Breast Cancer*, accepted [commentary]. [also under Breast Committee]

# Publication List by Committee

## Submitted Manuscripts

**S9217/Multiple** A pooled analysis of 15 prospective cohort studies on the association between fruit, vegetable, and mature bean consumption and risk of prostate cancer. J Petimar, KM Wilson, K Wu, D Albanes, PA van den Brandt, MB Cook, GG Giles, E Giovannucci, GG Goodman, PJ Goodman, N Håkansson, K Helzlsouer, LN Kolonel, LM Liao, S Männistö, ML McCullough, R Milne, ML Neuhouser, Y Park, EA Platz, N Sawada, JM Schenk, S Tsugane, B Verhage, M Wang, Y Wang, LR Wilkens, A Wolk, RG Ziegler, SA Smith-Warner. *American Journal of Epidemiology*, revised/resubmitted/under review.

**S9217** Interactions of the insulin-like growth factor axis and vitamin D in prostate cancer risk in the Prostate Cancer Prevention Trial. FL Miles, PJ Goodman, C Tangen, KC Torkko, JM Schenk, X Song, M Pollak, IM Thompson, ML Neuhouser. *Cancer Causes and Control*, under review.

## Symptom Control & Quality of Life Committee

### Published/Accepted Manuscripts

No publication information for this cycle.

### Submitted Manuscripts

**S0221** Supplement use and chemotherapy-induced peripheral neuropathy in patients treated in a SWOG cooperative group trial (S0221): the DELCaP Study. G Zirpoli, S McCann, L Sucheston-Campbell, D Hershman, G Ciupak, W Davis, J Unger, H Moore, JA Stewart, C Isaacs, T Hobday, M Salim, R Livingston, G Hortobagyi, J Gralow, D Hayes, G Budd, K Albain, C Ambrosone. *Journal of the National Cancer Institute*, under revision/pending resubmission. [also under Breast Committee]

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). MR Mahoney, JA Sloan, JM Hubbard, AD Tan, H Liu, RM Goldberg, SG Nair, AF Shields, S Gill, B Jahagirdar, AB Benson, DJ Sargent, SR Alberts. *Journal of Clinical Oncology*, submitted 1/30/17. [also under GI Committee]

## Early Therapeutics & Rare Cancers Committee

### Published/Accepted Manuscripts

**S8892/Multiple** What is the best treatment for locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. L Ribassin-Majed, S Marguet, AWM Lee, WT Ng, J Ma; ATC Chan; P-Yu HUANG, G Zhu, TTD Chua, Q Chen, H-Q Mai, DL Kwong, C Shie-Lee; J Moon, Y Tung, K-H Chi, G Fountzilas, J Bourhis, J-P Pignon, P Blanchard. *Journal of Clinical Oncology*, Feb 35(5):499-505, 2017. PMID27918720 <https://www.ncbi.nlm.nih.gov/pubmed/27918720>

**S8892/Multiple** Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. F Rotolo, J-P Pignon, J Bourhis, S Marguet, J Leclercq, WT Ng, J Ma, ATC Chan, P-Y Huang, G Zhu, DTT Chua, Y Chen, H-Q Mai, DLW Kwong, YL Soong, J Moon, Y Tung, K-H Chi, G Fountzilas, L Zhang, EP Hui, AWM Lee, P Blanchard, S Michiels on behalf of MAC-NPC Collaborative Group. *Journal of the National Cancer Institute*, 2016 Dec 7;109(4). pii: djw239. Print 2017 Apr. PMID27927756 <https://www.ncbi.nlm.nih.gov/pubmed/27927756>

**E4397** Pre-radiation chemotherapy for adult high-risk medulloblastoma, PNET and ependymoma: ECOG 4397. PL Moots, A O'Neill, H Londer, M Mehta, DT Blumenthal, GR Barger, ML Grunnet, MR Gilbert, S Grossman, D Schiff. *American Journal of Clinical Oncology*, 2016 Sep 15. [Epub ahead of print]. PMID27635620 <https://www.ncbi.nlm.nih.gov/pubmed/27635620>

## Submitted Manuscripts

No publication information for this cycle.

## Gastrointestinal Committee

### Published/Accepted Manuscripts

**S0033** Long-term results of imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) correlated with next generation sequencing results: SWOG phase III intergroup trial S0033. MC Heinrich, C Rankin, CD Blanke, GD Demetri, EC Borden, CW Ryan, M von Mehren, ME Blackstein, DA Priebe, WD Tap, RG Maki, CL Corless, JA Fletcher, K Owzar, JJ Crowley, RS Benjamin, LH Baker. *JAMA Oncology*, 2017 Feb 9 [Epub ahead of print]. PMID28196207 <https://www.ncbi.nlm.nih.gov/pubmed/28196207>

**S0518** Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in advanced, poor prognosis carcinoid patients: SWOG S0518. JC Yao, KA Guthrie, C Moran, JR Strosberg, MH Kulke, J Ang Chan, N Loconte, RR McWilliams, EM Wolin, B Mattar, S McDonough, H Chen, CD Blanke, HS Hochster. *Journal of Clinical Oncology*, in press.

**S1115** SWOG S1115: A randomized phase II intergroup trial of selumetinib and MK-2206 versus mFOLFOX in patients with metastatic pancreatic cancer after prior therapy. V Chung, S McDonough, PA Philip, D Cardin, A Wang-Gillam, L Hui, MA Tejani, TE Seery, IA Dy, T Al Baghdadi, AE Hendifar, LA Doyle, AM Lowy, KA Guthrie, CD Blanke, HS Hochster. *JAMA Oncology*, 2016 Dec 15 [Epub ahead of print]. PMID27978579 <https://www.ncbi.nlm.nih.gov/pubmed/27978579>



# Publication List by Committee

**N0147** Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance). P Singh, Q Shi, N Foster, A Grothey, S Nair, E Chane, A Shields, R Goldberg, S Gill, M Kahlenberg, F Sinicrope, D Sargent, SR Alberts. *Oncologist* 2016 Dec;21(12):1509-1521. Epub 2016 Nov 23. PMID27881709; PMC5153338. [also under Cancer Survivorship Committee] <https://www.ncbi.nlm.nih.gov/pubmed/27881709>

## Submitted Manuscripts

**S0713** SWOG S0713: A phase II study of cetuximab added to induction chemotherapy of oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer. CG Leichman, SL McDonough, SR Smalley, KG Billingsley, H-J Lenz, MA Beldner, AF Hezel, MR Velasco, KA Guthrie, CD Blanke, HS Hochster. *Clinical Colorectal Cancer*, submitted.

**C80405** Chemotherapy with cetuximab or bevacizumab as initial treatment for patients with KRAS wild type metastatic colorectal cancer: CALGB/SWOG 80405. AP Venook, D Niedzwiecki, H-J Lenz, F Innocenti, B Fruth, JA Meyerhardt, D Schrag, C Greene, BH O'Neil, JE Shaw, JN Atkins, A El-khoueiry, S Berry, BN Polite, EM O'Reilly, RM Goldberg, HS Hochster, RL Schilsky, MM Bertagnolli, RJ Mayer, CD Blanke. *JAMA* under review.

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). MR Mahoney, JA Sloan, JM Hubbard, AD Tan, H Liu, RM Goldberg, SG Nair, AF Shields, S Gill, B Jahagirdar, AB Benson, DJ Sargent, SR Alberts. *Journal of Clinical Oncology*, under review. [also under SXQOL Committee]

## Genitourinary Committee

**Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees**

## Published/Accepted Manuscripts

**S1014** Phase II trial of abiraterone acetate for metastatic prostate cancer with suboptimal biochemical response to hormone induction (SWOG S1014). TW Flaig, M Plets, M Hussain, N Agarwal, N Mitsiades, HA Deshpande, U Vaishampayan, IM Thompson. *JAMA Oncology*, in press.

**S1602** Bacillus Calmette-Guérin manufacturing and SWOG S1602 Intergroup clinical trial [editorial]. JJ Meeks, SP Lerner, RS Svatek. *Journal of Urology* 2017 Mar;197(3 Pt 1):538-540. PMID27992750 <https://www.ncbi.nlm.nih.gov/pubmed/27992750>

[ncbi.nlm.nih.gov/pubmed/27992750](https://www.ncbi.nlm.nih.gov/pubmed/27992750)

**S8710** Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. E Ojerholm, A Smith, W-T Hwang, BC Baumann, KN Tucker, SP Lerner, R Mamtani, B Boursi, JP Christodouleas. *Cancer* 2017 Mar 1;123(5):794-801. PMID27787873; PMC5319875 <https://www.ncbi.nlm.nih.gov/pubmed/27787873>

**CCTG PR3** Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P. *Journal of Clinical Oncology* 2015 Jul 1;33(19):2143-50. PMID25691677; PMC4477786 <https://www.ncbi.nlm.nih.gov/pubmed/25691677>

## Submitted Manuscripts

**S0421** Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421. G Sonpavde, GR Pond, M Plets, CM Tangen, MHA Hussain, PN Lara, Jr, A Goldkorn, MG Garzotto, PC Mack, CS Higano, NJ Vogelzang, IM Thompson, Jr, PW Twardowski, PJ Van Veldhuizen, Jr, N Agarwal, MA Carducci, J Monk, DI Quinn. *Clinical Genitourinary Cancer*, submitted.

## Leukemia Committee

## Published/Accepted Manuscripts

**S0333** Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. O Sala Torra, M Othus, D Williamson, B Wood, I Kirsch, H Robins, L Beppu, M O'Donnell, S Forman F Appelbaum, J Radich. *Blood, Biology of Blood and Marrow Transplantation* 2017Apr;23(4):691-696. PMID28062215 <https://www.ncbi.nlm.nih.gov/pubmed/28062215>

**S0805** US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. F Ravandi, M Othus, SM O'Brien, SJ Forman, CS Ha, JY Wong, MS Tallman, E Paietta, J Racevskis, GL Uy, M Horowitz, N Takebe, R Little, U Borate, P Kebriaei, L Kingsbury, HM Kantarjian, JP Radich, HP Erba, FR Appelbaum. *Blood Advances*, Dec 27; 1(3):250-259, 2016. Journal link: <http://www.bloodadvances.org/content/bloodadvances/1/3/250.full.pdf>

# Publication List by Committee

**Multiple Studies\*** Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials. X Qu, M Othus, J Davison, Y Wu, L Yan, E Estey, J Radich, H Erba, FR Appelbaum, M Fang. *Cancer* 2017 Feb 21. doi: 10.1002/cncr.30626. [Epub ahead of print]. PMID28222251. [\*studies: S8600, S9333, S9031, S9500, S9918, S0106, S0112]. <https://www.ncbi.nlm.nih.gov/pubmed/28222251>

**Multiple Studies\*** Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. S Mantha, DA Goldman, SM Devlin, J-W Lee, D Zannino, M Collins, D Douer, HJ Iland, MR Litzow, EM Stein, FR Appelbaum, RA Larson, R Stone, BL Powell, S Geyer, K Laumann, JM Rowe, H Erba, S Coutre, M Othus, JH Park, PH Wiernik, MS Tallman. *Blood* 2017 Jan 12 [Epub ahead of print]. PMID28082441 [\*studies S0521, E2491, C9710] <https://www.ncbi.nlm.nih.gov/pubmed/28082441>

**CALGB Multiple Studies\*** An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. W Stock, B Diouf, KR Crews, D Pei, C Cheng, K Laumann, S Mandrekar, S Luger, A Advani, RM Stone, RA Larson MD, WE Evans. *Clinical Pharmacology and Therapeutics* 2017 Mar;101(3):391-395. PMID27618250. [\*Studies C19802, C10403, C10102, C9862]. <https://www.ncbi.nlm.nih.gov/pubmed/27618250>

## Submitted Manuscripts

**S1117** A randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia CMML): North American Intergroup Study SWOG S1117. MA Sekeres, M Othus, A List, O Odenike, R Stone, SD Gore, M Litzow, R Buckstein, M Fang, D Roulston, C Bloomfield, A Moseley, Y Zhang, M. Velasco, R Gaur, E Atallah, EC Attar, F Appelbaum, H Erba. *Journal of Clinical Oncology*, resubmitted/ under review.

## Lung Committee

### Published/Accepted Manuscripts

**Multiple Studies\*/Other** A pooled analysis of individual patient data of concurrent chemoradiotherapy for stage 3 non-small-cell lung cancer in elderly patients compared to younger patients who participated in United States National Cancer Institute Cooperative Group studies. TE Stinchcombe, Y Zhang, EE Vokes, J Schiller, JD Bradley, Karen Kelly, W Curran, SE Schild, B Movsas, G Clamon, R Govindan, GR Blumenschein, MA Socinski, NE Ready, WL Akerley, HJ Cohen, H Pang, X Wang. *Journal of Clinical Oncology*, in press. [\*S0023]

**Multiple Studies/Other** Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. HH Pang, X Wang, T Stinchcombe, M Wong, P Cheng, A Kishor Ganti, D Sargent, Y Zhang, C Hu, S Mandrekar, M Redman, J Manola, R Schilsky, H Cohen, J Bradley, A Adjei, D Gandara, S Ramalingam, E Vokes. *Journal of Clinical Oncology* 2016 Sep 19 [Epub ahead of print]. PMID27646951 [also under CCD Committee] <https://www.ncbi.nlm.nih.gov/pubmed/27646951>

## Submitted Manuscripts

**S0819** A randomized, phase III study of carboplatin/paclitaxel or carboplatin/ paclitaxel/ bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer: SWOG S0819. R Herbst, M Redman, E Kim, T Semrad, L Bazhenova, G Masters, K Oettel, P Guaglianone, C Reynolds, A Karnad, S Arnold, M Varela-Garcia, J Moon, P Mack, C Blanke, F Hirsch, K Kelly, DR Gandara. *Journal of Clinical Oncology*, submitted 3/6/17

**S0905** Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemo-naïve patients with unresectable malignant pleural mesothelioma (SWOG S0905). AS Tsao, MD, J Moon, II Wistuba, MD, NJ Vogelzang, GP Kalemkerian, MW Redman, DR Gandara, K Kelly. *Journal of Thoracic Oncology*, submitted 3/10/17.

## Lymphoma Committee

### Published/Accepted Manuscripts

**S0016/Other** Recommendations for clinical trial development in follicular lymphoma. K Maddocks, PM Barr, BD Cheson, RF Little, L Baizer, BS Kahl, JP Leonard, N Fowler, LI Gordon, BK Link, JW Friedberg, SM Ansell. *Journal of the National Cancer Institute*, Dec 31;109(3) pii: djw255, 2016. PMID28040699 <https://www.ncbi.nlm.nih.gov/pubmed/28040699>

**S0816** Reply to H.J.A. Adams et al and E.A. Hawkes et al. [correspondence.] O Press, J Friedberg. *Journal of Clinical Oncology*. DOI: 10.1200/JCO.2016.69.7979; [online before print October 28, 2016]. PMID27069074 <http://ascopubs.org/doi/pdf/10.1200/JCO.2016.69.7979>

**S1106** RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. RW Chen, H Li, SH Bernstein, S Kahwash, LM Rimsza, SJ Forman, L Constine, TC Shea, AF Cashen, KA Blum, TS Fenske, PM Barr, T Phillips, M Leblanc, RI Fisher, BD Cheson, SM Smith, M Faham, J Wilkins, JP Leonard, BS Kahl, JW Friedberg. *British Journal of Haematology*, 2017 Mar;176(5):759-769. PMID27992063; PMC5318240 <https://www.ncbi.nlm.nih.gov/pubmed/?term=chen+r+s1106>

# Publication List by Committee

**Multiple Studies\*/Other** T-cell lymphoma: recent advances in characterization and new opportunities for treatment. C Casulo, O O'Connor, A Shustov, M Fanale, JW Friedberg, JP Leonard, BS Kahl, RF Little, L Pinter-Brown, R Advani, S Horwitz. *Journal of the National Cancer Institute*, 2016 Dec 31;109(2). pii: djw248. PMID28040682. [\*studies S0350, S1108] <https://www.ncbi.nlm.nih.gov/pubmed/28040682>

**Multiple Studies\*/Other** Recommendations for clinical trial development in mantle cell lymphoma. SE Spurgeon, BG Till, P Martin, AH Goy, MP Dreyling, AK Gopal, M LeBlanc, JP Leonard, JW Friedberg, L Baizer, RF Little, BS Kahl, MR Smith. *Journal of the National Cancer Institute*, 2016 Dec 31;109(1). pii: djw263. PMID28040733. [\*studies S0601, S0213, S0108] <https://www.ncbi.nlm.nih.gov/pubmed/28040733>

**Multiple Studies\*** Beyond RCHOP: A blueprint for diffuse large B-cell lymphoma research. GS Nowakowski, KA Blum, BS Kahl, JW Friedberg, L Baizer, RF Little, DG Maloney, LH Sehn, ME Williams, WH Wilson, JP Leonard, SM Smith. *Journal of the National Cancer Institute*, 2016 Dec 16;108(12). pii: djw257. PMID27986884. [studies \*S9704, S0433, S0515] <https://www.ncbi.nlm.nih.gov/pubmed/27986884>

**S0816/Other** Hodgkin lymphoma: Current status and clinical trial recommendations. CS Diefenbach, JM Connors, JW Friedberg, JP Leonard, BS Kahl, RF Little, L Baizer, AM Evens, RT Hoppe, KM Kelly, DO Persky, A Younes, L Kostakoglu, NL Bartlett. *Journal of the National Cancer Institute*, Dec 31;109(4). pii: djw249, 2016. PMID28040700 <https://www.ncbi.nlm.nih.gov/pubmed/28040700>

**Study N/A** General biomarker recommendations for lymphoma. L Rimsza, Y Fedoriw, LM Staudt, A Melnick, R Gascoyne, M Crump, L Baizer, K Fu, E Hsi, JWC Chan, L McShane, JP Leonard, BS Kahl, RF Little, JW Friedberg, L Kostakoglu. *Journal of the National Cancer Institute*, 2016 Dec 16;108(12). pii: djw250. Print 2016 Dec. PMID27986882 <https://www.ncbi.nlm.nih.gov/pubmed/27986882>

**E4494** Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793; ECOG-SWOG 4494). VA Morrison, EA Weller, TM Habermann, S Li S, RI Fisher, RI, BD Cheson, BA Peterson. *Leukemia & Lymphoma* 2016 Dec 14;1-9. PMID27967294 <https://www.ncbi.nlm.nih.gov/pubmed/27967294>

## Submitted Manuscripts

No publication information for this cycle.

## MELANOMA COMMITTEE

## Published/Accepted Manuscripts

**E1697** Phase III Randomized Study of 4 Weeks of High-Dose Interferon- $\alpha$ -2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). SS Agarwala, SJ Lee, W Yip, U Rao, A Tarhini, GI Cohen, DS Reintgen, TL Evans, J Brell, M Albertini, M Atkins, S Dakhil, R Conry, J Sosman, L Flaherty, V Sondak, WE Carson, M Smylie, A Pappo, R Kefford, J Kirkwood. *Journal of Clinical Oncology* 2017 Mar 10;35(8):885-892. PMID28135150 <https://www.ncbi.nlm.nih.gov/pubmed/28135150>

**E2607** A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral and vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607). K Kalinsky, S Lee, K Rubin, DP Lawrence, AJ Lafrarte, DR Borger, KA Margolin, MM Leitao, Jr, AA Tarhini, HB Koon, AL Pecora, AJ Jaslawski, GI Cohen, TM Kuzel, CD Lao, JM Kirkwood. *Journal of Clinical Oncology*, in press.

## Submitted Manuscripts

No publication information for this cycle.



# \$250,000

## To VA Medical Centers Since 2015

### To Improve Veterans' Access to National Clinical Trials Network Cancer Clinical Trials



THE HOPE FOUNDATION

*Because answers to cancers come from clinical trials*



Special thanks to our  
2017 Group Meeting Commercial Supporters\*

# We value their partnership.

## CME



PLATINUM

Lilly  
Celgene



GOLD

Novartis



SILVER

Merck  
Genomic Health



BRONZE

Bristol-Myers Squibb

## Non-CME



GOLD

Takeda Oncology

### 2017 EXHIBITORS

Omniseq  
Gilead Sciences, Inc.  
Novartis  
Guardant Health  
Taiho Oncology, Inc.  
Boehringer Ingelheim  
AstraZeneca  
AbbVie  
Seattle Genetics  
Pharmacylics

\* Supporters as of March 27, 2017



## Notes

Let's Make More Time

